Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L15	55957	antisense or triplex or ribozyme or RNAi or siRNA or "RNA interfer?" or "short interfer? RNA"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 10:58
L16	186	"human x-linked inhibitor of apoptosis" or hiap-1 or xiap or "x-linked iap" or "miha protein"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 10:59
L17	102723	cancer? or tumor? or carcinoma? or tumour?	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 11:00
L18	43	"follicular atresia?" or "atresia? follicular"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 11:00
L19	8642	"inflammatory disorder"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 12:04
L20	124	L15 AND L16	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 11:01
L21	96	L20 AND L17	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 11:02
L22	1	L20 AND L18	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 12:02
L23	5	L20 AND L19	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 12:03
L24	812	"inflamm? disease" or "inflamm?" or "inflamm? disorder"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 12:04
L25	23	"inflammat? disease" or "inflammat?" or "inflammat? disorder"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 12:04
L26	111793	inflammatory	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 12:04

L27	66	L20 AND L26	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2004/11/15 12:05

```
Set      Items     Description
S1        4667     XIAP OR HIAP OR HILP OR MIHA
S2      213803     ANTISENSE OR RIBOZYME OR TRIPLEX OR SIRNA OR RNAI OR (SHORT
                   INTERFER? RNA)
S3     7369699     CANCER OR TUMOR OR CARCINOMA
S4        1106     FOLLICULAR ATRESIA?
S5     1627772     INFLAMMAT?
S6         287     S1 AND S2
S7          89     RD S6 (unique items)
S8          61     S7 AND S3
S9          61     RD S8 (unique items)
S10          0     S7 AND S4
S11          3     S7 AND S5
? t s8/free/all
>>>"FREE" is not a valid format name in file(s): 399
```

8/6/1   (Item 1 from file: 5)
0015002823   BIOSIS NO.: 200400373612
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs
sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis
2004

8/6/2   (Item 2 from file: 5)
0014973429   BIOSIS NO.: 200400344218
Enhancement of C2-ceramide antitumor activity by small interfering RNA on X
chromosome-linked inhibitor of apoptosis protein in resistant human
glioma cells
2004

8/6/3   (Item 3 from file: 5)
0014959816   BIOSIS NO.: 200400330602
X-linked inhibitor of apoptosis protein inhibition induces apoptosis and
enhances chemotherapy sensitivity in human prostate cancer cells
2004

8/6/4   (Item 4 from file: 5)
0014945078   BIOSIS NO.: 200400315835
Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7
cells by a mechanism of NF-kappaB-dependent XIAP up-regulation
2004

8/6/5   (Item 5 from file: 5)
0014905560   BIOSIS NO.: 200400276317
Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects
of chemotherapeutic agents in MCF-7 human breast cancer cells
2004

8/6/6   (Item 6 from file: 5)
0014846985   BIOSIS NO.: 200400217040
Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia.
2003

8/6/7   (Item 7 from file: 5)
0014818352   BIOSIS NO.: 200400186038
Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis
   protein (XIAP).
2004

8/6/8   (Item 8 from file: 5)
0014795073   BIOSIS NO.: 200400162414
Mechanisms of apoptosis induction by a novel ring-substituted
   diindolylmethane (1,1-bis (3'-(5-methoxy indolyl))-1-(p-t-butylphenyl)
   methane) (BMIPTM) in leukemic cells.
2003

8/6/9   (Item 9 from file: 5)
0014780228   BIOSIS NO.: 200400146889
The triterpenoid CDDO-imidazolide induces apoptosis of CLL B-cells, through
   a Bcl-2-independent mechanism and synergizes with fludarabine.
2003

8/6/10   (Item 10 from file: 5)
0014730212   BIOSIS NO.: 200400100969
Induction of cIAP-2 in human colon cancer cells through
   PKCdelta/NF-kappaB.
2003

8/6/11   (Item 11 from file: 5)
0014727376   BIOSIS NO.: 200400098133
 RNAi mediated downregulation of bcl-2 and xlAP may have therapeutical
   potential in human breast adenocarcinoma.
2003

8/6/12   (Item 12 from file: 5)
0014581909   BIOSIS NO.: 200300538099
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the
   cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and
   NF-kappaB-dependent process.
2003

8/6/13   (Item 13 from file: 5)
0014387492   BIOSIS NO.: 200300346211
The histone deacetylase inhibitor MS-275 promotes differentiation or
   apoptosis in human leukemia cells through a process regulated by
   generation of reactive oxygen species and induction of p21CIP1/WAF1.
2003

8/6/14   (Item 14 from file: 5)
0014380229   BIOSIS NO.: 200300336972
Bcl-2 Antisense Treatment for Waldenstrom's Macroglobulinemia.
2002

8/6/15   (Item 15 from file: 5)
0014080092   BIOSIS NO.: 200300038811
Role of XIAP in the malignant phenotype of transitional cell cancer
   (TCC) and therapeutic activity of xiap   antisense oligonucleotides
   against multidrug-resistant TCC in vitro.
2003

8/6/16   (Item 16 from file: 5)
0013916537   BIOSIS NO.: 200200510048
A novel tri-specific antisense oligonucleotide (AO) to the Inhibitors of
   Apoptosis Proteins (IAPs) enhances apoptosis in PC3 prostate cancer
   cells
2002

8/6/17   (Item 17 from file: 5)
0013815621   BIOSIS NO.: 200200409132
 Antisense oligonucleotides targeting XIAP induce apoptosis and enhance
   therapeutic activity against human lung cancer cells when combined with
   anticancer drug in vitro and in vivo
2002

8/6/18   (Item 18 from file: 5)
0013365117   BIOSIS NO.: 200100536956
Survivin inhibition induces human neural tumor cell death through
   caspase-independent and -dependent pathways
2001

8/6/19   (Item 19 from file: 5)
0013254012   BIOSIS NO.: 200100425851
Identification of p21 as a target of cycloheximide-mediated facilitation of
   CD95-mediated apoptosis in human malignant glioma cells
2001

8/6/20   (Item 20 from file: 5)
0013249225   BIOSIS NO.: 200100421064
 XIAP : Apoptotic brake and promising therapeutic target
2001

8/6/21   (Item 21 from file: 5)
0013237922   BIOSIS NO.: 200100409761
Gene therapy that inhibits nuclear translocation of nuclear factor kappaB
   results in tumor necrosis factor alpha-induced apoptosis of human
   synovial fibroblasts
2000

8/6/22   (Item 22 from file: 5)
0012930183   BIOSIS NO.: 200100102022
Nuclear factor-kappaB-mediated X-linked inhibitor of apoptosis protein
   expression prevents rat granulosa cells from tumor necrosis factor

alpha-induced apoptosis
2001

8/6/23   (Item 23 from file: 5)
0012919888   BIOSIS NO.: 200100091727
Human ovarian cancer and cisplatin resistance: Possible role of inhibitor
  of apoptosis proteins
2001

8/6/24   (Item 24 from file: 5)
0012897193   BIOSIS NO.: 200100069032
Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated
  apoptosis by down-regulating FLIP-L expression
2000

8/6/25   (Item 25 from file: 5)
0012810857   BIOSIS NO.: 200000529170
Down-regulation of X-linked inhibitor of apoptosis protein induces
  apoptosis in chemoresistant human ovarian cancer cells
2000

8/6/26   (Item 26 from file: 5)
0012731647   BIOSIS NO.: 200000449960
Translational upregulation of X-linked inhibitor of apoptosis (XIAP)
  increases resistance to radiation induced cell death
2000

8/6/27   (Item 27 from file: 5)
0012655181   BIOSIS NO.: 200000373494
Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by
  down-regulating Fas-associated death domain-like interleukin 1-converting
  enzyme inhibitory protein expression
2000

8/6/28   (Item 28 from file: 5)
0012599835   BIOSIS NO.: 200000318148
Apoptosis and chemoresistance in human ovarian cancer : Is Xiap a
  determinant?
2000

8/6/29   (Item 1 from file: 440)
19534580 Document Delivery Available: 000224692500008 References: 58
TITLE: Loss of XIAP protein expression by RNAi and antisense
    approaches sensitizes cancer cells to functionally diverse
    chemotherapeutics (ABSTRACT AVAILABLE)
2004
GENUINE ARTICLE#: 865HE

8/6/30   (Item 2 from file: 440)

19532380 Document Delivery Available: 000224732800007 References: 54
TITLE: Potent antileukemic interactions between flavopiridol and
    TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation (
  ABSTRACT AVAILABLE)
2004
GENUINE ARTICLE#: 865VR

   8/6/31   (Item 3 from file: 440)
19532375 Document Delivery Available: 000224732800002 References: 158
TITLE: Inhibitor of apoptosis proteins: new therapeutic targets in
    hematological cancer ?   (ABSTRACT AVAILABLE)
2004
GENUINE ARTICLE#: 865VR

   8/6/32   (Item 4 from file: 440)
19524265 Document Delivery Available: 000224756000008 References: 46
TITLE: IFN-gamma enhances TRAIL-induced apoptosis through IRF-1   (ABSTRACT
  AVAILABLE)
2004
GENUINE ARTICLE#: 866EG

   8/6/33   (Item 5 from file: 440)
19519481 Document Delivery Available: 000224701500004 References: 72
TITLE: The inhibitor of apoptosis protein family and its antagonists in
    acute leukemias (ABSTRACT AVAILABLE)
2004
GENUINE ARTICLE#: 865KL

   8/6/34   (Item 6 from file: 440)
19358336 Document Delivery Available: 000224076900013 References: 33
TITLE: Down-regulation of procaspase-8 expression by focal adhesion kinase
    protects HL-60 cells from TRAIL-induced apoptosis (ABSTRACT AVAILABLE)
2004
GENUINE ARTICLE#: 856WS

   8/6/35   (Item 7 from file: 440)
19289502 Document Delivery Available: 000223885100005 References: 28
TITLE: XIAP and survivin as therapeutic targets for radiation
    sensitization in preclinical models of lung cancer   (ABSTRACT
  AVAILABLE)
2004
GENUINE ARTICLE#: 854EX

   8/6/36   (Item 8 from file: 440)
16717231 Document Delivery Available: 000184578900004 References: 39
TITLE: Loss of inhibitor of apoptosis proteins as a determinant of
    polyamine analog-induced apoptosis in human melanoma cells (ABSTRACT
  AVAILABLE)
2003
GENUINE ARTICLE#: 708QF

8/6/37   **(Item 9 from file: 440)**
16540070 Document Delivery Available: 000184108700056 References: 40
TITLE: Antisense **oligonucleotides targeting** XIAP **induce apoptosis and**
    enhance chemotherapeutic activity against human lung cancer **cells in**
    vitro and in vivo (ABSTRACT AVAILABLE)
2003
GENUINE ARTICLE#: 700JK

8/6/38   **(Item 10 from file: 440)**
14870510 Document Delivery Available: 000178519100042 References: 44
TITLE: The triterpenoid CDDO induces apoptosis in refractory CLL B cells (
  ABSTRACT AVAILABLE)
2002
GENUINE ARTICLE#: 602RW

8/6/39   **(Item 11 from file: 440)**
12401967 References: 47
TITLE: Livin, a novel inhibitor of apoptosis protein family member (
  ABSTRACT AVAILABLE)
2001
GENUINE ARTICLE#: 398YW

8/6/40   **(Item 1 from file: 155)**

16255410 PMID: 14990073
  [Expression and significance of apoptosis protein inhibitor survivin and
  XIAP , **in** **patients with myelodysplastic syndromes and in the cell line**
MUTZ-1]
Jan 2004
  Tags: Human; Support, Non-U.S. Gov't
  Descriptors: *Apoptosis;   *Harringtonines--therapeutic   use--TU;
*Microtubule-Associated Proteins--genetics--GE; *Myelodysplastic Syndromes
--pathology--PA; *Proteins--genetics--GE; Apoptosis--drug effects--DE; Cell
Cycle--drug   effects--DE;   Cell   Division--drug   effects--DE;
Microtubule-Associated Proteins--physiology--PH; Myelodysplastic Syndromes
--drug therapy--DT; Oligonucleotides, **Antisense** --pharmacology--PD;
Proteins--physiology--PH; RNA, Messenger--analysis--AN
  CAS Registry No.: 0   (Harringtonines); 0   (IAP-like protein, vertebrate)
; 0   (Microtubule-Associated Proteins); 0   (Oligonucleotides, Antisense);
0   (Proteins);   0   (RNA,   Messenger); 0   (survivin); 26833-87-4
  (homoharringtonine)

8/6/41   **(Item 2 from file: 155)**

14387430 PMID: 10381630
  Expression and biological activity of X-linked inhibitor of apoptosis (
  XIAP) in human malignant glioma.
Apr 1999
  Tags: Human; Support, Non-U.S. Gov't
  Descriptors: *Apoptosis--genetics--GE; *Brain Neoplasms; *Gene Expression
Regulation, Neoplastic; *Glioma; Adenoviridae--genetics--GE; Antigens, CD95
--genetics--GE; **Antisense** Elements (Genetics); Caspases--metabolism--ME;

Gene Transfer Techniques; Neoplasm Proteins--genetics--GE; Proteins --genetics--GE; **Tumor** Cells, Cultured--enzymology--EN; **Tumor** Cells, Cultured--pathology--PA; **Tumor** Cells, Cultured--physiology--PH
CAS Registry No.: 0 (Antigens, CD95); 0 (Antisense Elements (Genetics)); 0 (IAP-like protein, vertebrate); 0 (Neoplasm Proteins); 0 (Proteins)
Enzyme No.: EC 3.4.22.- (Caspases)

8/6/42 (Item 3 from file: 155)

12432968 PMID: 12839953
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
Jul 1 2003
Tags: Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
Descriptors: *Apoptosis--drug effects--DE; *Benzamides--pharmacology--PD; *Cell Differentiation--drug effects--DE; *Cyclins--metabolism--ME; *Histone Deacetylases--antagonists and inhibitors--AI; *Pyridines--pharmacology--PD; *Reactive Oxygen Species--metabolism--ME; Cell Cycle--drug effects--DE; Cell Division--drug effects--DE; HL-60 Cells; Intracellular Membranes--drug effects--DE; Intracellular Membranes--physiology--PH; K562 Cells; Leukemia ; Membrane Potentials--drug effects--DE; Mitochondria--drug effects--DE; Mitochondria--physiology--PH; **Tumor** Cells, Cultured; U937 Cells
CAS Registry No.: 0 (Benzamides); 0 (Cip1 protein); 0 (Cyclins); 0 (N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide); 0 (Pyridines); 0 (Reactive Oxygen Species)
Enzyme No.: EC 3.5.1.- (Histone Deacetylases)

8/6/55 (Item 1 from file: 73)
12163838 EMBASE No: 2003265557
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21SUPCIP1/WAF1
01 JUL 2003

8/6/56 (Item 2 from file: 73)
11968278 EMBASE No: 2003076858
Resistance of human ovarian cancer **cells to** tumor **necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein**
01 FEB 2003

8/6/57 (Item 3 from file: 73)
11942842 EMBASE No: 2003053287
Regulation of Apo2L/ tumor **necrosis factor-related apoptosis**-inducing **ligand-induced apoptosis in thyroid** carcinoma **cells**
2002

8/6/58 (Item 4 from file: 73)
11088683 EMBASE No: 2001106169

Nuclear factor-kappaB-mediated X-linked inhibitor of apoptosis protein expression prevents rat granulosa cells from tumor necrosis factor alpha-induced apoptosis
    2001

8/6/59   (Item 1 from file: 144)
DIALOG(R)File 144:(c) 2004 INIST/CNRS. All rts. reserv.

  16306294   PASCAL No.: 03-0470411
  Antisense **oligonucleotides targeting** XIAP **induce apoptosis and enhance chemotherapeutic activity against human lung** cancer **cells in vitro and in vivo**
    2003

English Descriptors: Human; In vitro; Established cell line; Malignant
  tumor ; Bronchopulmonary; **Tumor** cell; Biological activity; Animal;
  Mouse; In vivo; Treatment; Antineoplastic agent; Chemotherapy; Drug
  combination; **Antisense** oligonucleotide; Potentiation; Apoptosis; Cell
  death; Apoptosis inhibitory protein
Broad Descriptors: Rodentia; Mammalia; Vertebrata; Respiratory disease;
  Lung disease; Bronchus disease; Rodentia; Mammalia; Vertebrata; Appareil
  respiratoire pathologie; Poumon pathologie; Bronche pathologie; Rodentia;
  Mammalia; Vertebrata; Aparato respiratorio patologia; Pulmon patologia;
  Bronquio patologia

French Descriptors: Homme; In vitro; Lignee cellulaire etablie; Tumeur
  maligne; Bronchopulmonaire; Cellule tumorale; Activite biologique; Animal
  ; Souris; In vivo; Traitement; Anticancereux; Chimiotherapie; Association
  medicamenteuse; Oligonucleotide antisens; Potentialisation; Apoptose;
  Mort cellulaire; Gene **XIAP** ; Proteine inhibition apoptose

Classification Codes: 002B02R02

 Copyright (c) 2003 INIST-CNRS. All rights reserved.

8/6/60   (Item 2 from file: 144)
DIALOG(R)File 144:(c) 2004 INIST/CNRS. All rts. reserv.

  15534948   PASCAL No.: 02-0233325
  Survivin inhibition induces human neural tumor **cell death through caspase-independent and -dependent pathways**
    2001

English Descriptors: Apoptosis; **Tumor** cell; Cell death; Cysteine
  endopeptidases; Caspase; Human
Broad Descriptors: Peptidases; Hydrolases; Enzyme; Peptidases; Hydrolases;
  Enzyme; Peptidases; Hydrolases; Enzima

French Descriptors: Apoptose; Cellule tumorale; Mort cellulaire; Cysteine
  endopeptidases; Caspase; Homme; Survivine

Classification Codes: 002B04G01

 Copyright (c) 2002 INIST-CNRS. All rights reserved.

8/6/61   (Item 3 from file: 144)

14624714   PASCAL No.: 00-0295143
**Gene therapy that inhibits nuclear translocation of nuclear factor KB
results in** tumor **necrosis factor** alpha **-induced apoptosis of human
synovial fibroblasts**
2000

English Descriptors: Rheumatoid arthritis; Treatment; Chemotherapy; Gene
   therapy; Mechanism of action; Inhibition; Translocation; Apoptosis; Cell
   death; **Tumor** necrosis factor alpha ; Fibroblast; Synovial membrane; In
   vitro; Human; Tissue culture; Chronic; Transcription factor NF kappa B
Broad Descriptors: Diseases of the osteoarticular system; Inflammatory
   joint disease; Immunopathology; Autoimmune disease; Cytokine; Systeme
   osteoarticulaire pathologie; Rhumatisme inflammatoire; Immunopathologie;
   Maladie autoimmune; Cytokine; Sistema osteoarticular patologia;
   Reumatismo inflamatorio; Inmunopatologia; Enfermedad autoinmune;
   Citoquina

French Descriptors: Polyarthrite rhumatoide; Traitement; Chimiotherapie;
   Therapie genique; Mecanisme action; Inhibition; Translocation; Apoptose;
   Mort cellulaire; Facteur necrose tumorale alpha ; Fibroblaste; Synoviale
   ; In vitro; Homme; Culture tissu; Chronique; Facteur transcription NF
   kappa B

Classification Codes: 002B15D

?

t s11/medium, k/all
>>>KWIC option is not available in file(s): 399

11/K/1   (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0013914248   BIOSIS NO.: 200200507759
CD40 engagement enhances eosinophil survival through induction of cellular
  inhibitor of apoptosis protein 2 expression: Possible involvement in
  allergic inflammation
AUTHOR: Bureau Fabrice (Reprint); Seumois Gregory; Jaspar Fabrice;
  Vanderplasschen Alain; Detry Bruno; Pastoret Paul-Pierre; Louis Renaud;
  Lekeux Pierre
AUTHOR ADDRESS: Department of Physiology, Faculty of Veterinary Medicine,
  University of Liege, Sart Tilman, Bat. B42, B-4000, Liege, Belgium**
  Belgium
JOURNAL: Journal of Allergy and Clinical Immunology 110 (3): p443-449
September, 2002 2002
MEDIUM: print
ISSN: 0091-6749
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

...survival through induction of cellular inhibitor of apoptosis protein 2
  expression: Possible involvement in allergic inflammation
...ABSTRACT: of the inhibitor of apoptosis protein (IAP) family, namely
  cellular (c)-IAP1, c-IAP2, and **XIAP** , and 2 antiapoptotic proteins of
  the Bcl-2 family, namely Bcl-xL and Bfl-1...

...staining with propidium iodide and FITC-conjugated annexin-V. c-IAP2
  expression was inhibited with **antisense** oligonucleotides. Results:
  Freshly isolated eosinophils from healthy and asthmatic patients did not
  express CD40. Conversely...

...Inhibition of eosinophil apoptosis was accompanied by induction of
  c-IAP2 but not c-IAP1, **XIAP** , Bcl-xL, or Bfl-1/A1 expression. **Antisense**
  knockdown of c-iap2 abolished CD40-induced enhancement of eosinophil
  survival. Sputum cells from asthmatic...

...through induction of c-IAP2 expression and suggest a role for this
  mechanism in allergic **inflammation** .
DESCRIPTORS:
  DISEASES: allergic **inflammation** --
  CHEMICALS & BIOCHEMICALS: ...X-inhibitor of apoptosis protein (**XIAP**);

11/K/2   (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.

  141307497   CA: 141(19)307497m   PATENT
  Use of caspase inhibitors as antiviral agents, and test system for their
discovery
  INVENTOR(AUTHOR): Ludwig, Stefan; Planz, Oliver; Sedlacek, Hans-Harald;
Pleschka, Stephan
  LOCATION: Germany,

ASSIGNEE: Medinnova Gesellschaft fur Medizinische Innovationen aus Akademischer Forschung m.b.H.
    PATENT: PCT International ; WO 200485682 A2   DATE: 20041007
    APPLICATION: WO 2004DE646 (20040324) *DE 10313636 (20030326)
    PAGES: 40 pp.   CODEN: PIXXD2   LANGUAGE: German   CLASS: C12Q-001/70A
    DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW   DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ
; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE;
BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL;
PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE;
SN; TD; TG

11/K/3   (Item 1 from file: 144)
DIALOG(R)File 144:Pascal
(c) 2004 INIST/CNRS. All rts. reserv.

    14624714   PASCAL No.: 00-0295143
    **Gene therapy that inhibits nuclear translocation of nuclear factor KB
results in tumor necrosis factor alpha -induced apoptosis of human
synovial fibroblasts**
    ZHANG H G; NING HUANG; DI LIU; BILBAO L; XIAOWU ZHANG; YANG P; TONG ZHOU;
CURIEL D T; MOUNTZ J D
    University of Alabama at Birmingham, United States; Gene Therapy Program,
Birmingham, Alabama, United States; University of Alabama at Birmingham,
Birmingham, Alabama, United States; Veterans Administration Medical Center,
Birmingham, Alabama, United States
    Journal: Arthritis and rheumatism, 2000, 43 (5) 1094-1105
    Language: English

Copyright (c) 2000 INIST-CNRS. All rights reserved.

    ... factor KB (IKB) dominant-negative adenovirus (AdCMVIKB-DN) and an
X-linked inhibitor of apoptosis (**XIAP**) **antisense** adenovirus
(AdCMVXIAP-AS). Primary RA synovial fibroblast (RASF) cell lines were
transfected in vitro, and...

... was no apoptosis after treatment with AdCMVI kappa B-DN in the absence
of TNFa.   **XIAP** is an inhibitor of apoptosis which was up-regulated by
TNFa, and this up-regulation...

... greatly enhances apoptosis due to inhibition of an NF-KB-mediated
antiapoptosis signaling pathway, and **XIAP** is a TNFa-inducible specific
inhibitor of apoptosis in RA synovial cell lines. This and...
Broad Descriptors: Diseases of the osteoarticular system; **Inflammatory**
  joint disease; Immunopathology; Autoimmune disease; Cytokine; Systeme
  osteoarticulaire pathologie; Rhumatisme **inflammatoire** ; Immunopathologie
  ; Maladie autoimmune; Cytokine; Sistema osteoarticular patologia;
  Reumatismo inflamatorio; Inmunopatologia; Enfermedad autoinmune;
  Citoquina
?

QM nucleic - nucleic search, using sw model

Run on: November 15, 2004, 08:25:47 ; Search time 0.001 Seconds
(without alignments)
40.400 Million cell updates/sec

Copyright (c)   GenCore version 5.1.6
1993 - 2004 Compugen Ltd.

Title: US-10-070-789-8
Perfect score: 20
Sequence: 1 taggacttgtcaccttc 20
Run on: November 15, 2004, 08:25:47

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 99 seqs, 1010 residues

Total number of hits satisfying chosen parameters: 198

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 99 summaries

Database : fetchrng8.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Query Length	DB	ID	Description
1	20	100.0	20	1	AAA64908	Antisense oligonuc
2	11.4	57.0	13	1	ABF25765	Oligonucleotide SE
3	11.4	57.0	13	1	ABF25764	Oligonucleotide SE
4	11	55.0	13	1	ABF81742	Oligonucleotide SE
5	11	55.0	13	1	ABF81743	Oligonucleotide SE
6	10.4	52.0	13	1	ABH12912	Oligonucleotide SE
7	10.4	52.0	13	1	ABH12913	Oligonucleotide SE
8	10	50.0	10	1	AA284451	Metastatic breast
9	10	50.0	10	1	AAQ72345	Human CYP2D6 gene
10	10	50.0	11	1	ABV71425	Human skin EST 921
11	10	50.0	11	1	ABV64836	Human skin EST 262
12	10	50.0	11	1	ABV64004	Human skin EST 179
13	10	50.0	12	1	ABI11479	Oligonucleotide pr
14	9.4	47.0	11	1	ADQ35262	Human hair-bearing
15	9	45.0	10	1	AA282410	Metastatic breast
16	9	45.0	10	1	AA283740	Metastatic breast
17	9	45.0	10	1	AAF34752	Yeast NORF gene SA
18	9	45.0	10	1	AAF34921	Yeast NORF gene SA
19	8.4	42.0	10	1	AAQ96595	HIV-1 NL4-3 nef ge
20	8.4	42.0	10	1	AAQ96682	HIV-1 NL4-3 nef ge
21	8.4	42.0	10	1	AAX60279	M13 primer used t
22	8.4	42.0	10	1	AA282548	Metastatic breast
23	8.4	42.0	10	1	AA284690	Metastatic breast
24	8.4	42.0	10	1	AA284672	Metastatic breast
25	8.4	42.0	10	1	AA281424	Metastatic breast
26	8.4	42.0	10	1	AA281367	Metastatic breast
27	8.4	42.0	10	1	AA284746	Metastatic breast
28	8.4	42.0	10	1	AA280933	Metastatic breast
29	8.4	42.0	10	1	AA284569	Metastatic breast
30	8.4	42.0	10	1	ABA81664	Human phospholipid
31	8.4	42.0	10	1	ABA81653	Human phospholipid
32	8.4	42.0	10	1	AAF42786	Yeast NORF gene SA
33	8.4	42.0	10	1	AAF41677	Yeast NORF gene SA
34	8.4	42.0	10	1	ABL88346	Human CHRNE gene p
35	8.4	42.0	10	1	ABK85694	Human SCYB6 gene p
36	8.4	42.0	10	1	ABV84283	Human alpha-1-anti
37	8.4	42.0	10	1	ABV84516	Human multiple HCC
38	8.4	42.0	10	1	ABK23590	Transcript tag DNA
39	8.4	42.0	10	1	ABL11889	Human LIPG gene pr
40	8.4	42.0	10	1	AAL40865	Zinc finger protei
41	8.4	42.0	10	1	AAS94665	Human PTP gene al
42	8.4	42.0	10	1	AAS46676	Human PTP gene al
43	8.4	42.0	10	1	ABN85904	Gamma tocopherol m
44	8.4	42.0	10	1	ADN00986	Human CETP gene al
45	8.4	42.0	10	1	ADG98610	Human ADOB gene a
46	8.4	42.0	10	1	ACF57642	Human ADOB gene a
47	8.4	42.0	10	1	ADJ78755	Arabidopsis gamma-
48	8.4	42.0	10	1	ADI13651	Extracellular tumo
49	8.4	42.0	10	1	ADK12872	Human glioma endot
50	8	40.0	8	1	AAT09494	Gamma-tocopherol m
51	8	40.0	8	1	AAT05675	5'-primer used for
52	8	40.0	8	1	AAB80917	3'-primer used for
53	8	40.0	8	1	AAA81227	A. thaliana primer
54	8	40.0	8	1	AAA80895	A. thaliana primer
55	8	40.0	8	1	ADC45730	A. thaliana primer
56	8	40.0	8	1	ADC45731	Nucleic acid-synth
57	8	40.0	8	1	AAZ79551	Nucleic acid-synth
58	8	40.0	8	1	AAZ79431	Seq ID #45 from WO
59	8	40.0	8	1	AAV11229	Nilaparvata lugens
60	8	40.0	8	1	AAZ08340	Nilaparvata lugens
61	8	40.0	8	1	AAZ08337	Human dendritic ce
62	8	40.0	8	1	AAH20011	Human dendritic ce
63	8	40.0	8	1	AAH63882	Metastatic breast
64	8	40.0	8	1	AA285883	Metastatic breast
65	8	40.0	8	1	AAZ81064	Metastatic breast
66	8	40.0	8	1	AAZ83375	Metastatic breast
67	8	40.0	8	1	AAZ83135	Human monocyte gen
68	8	40.0	8	1	AAZ83682	Mouse Treg immunor
69	8	40.0	8	1	AAA56174	Human ubiquitously
70	8	40.0	8	1	AAH62011	Human ubiquitously
71	8	40.0	8	1	AAH63884	Human ubiquitously
72	8	40.0	8	1	AAH63882	Human colon cancer
73	8	40.0	8	1	AAH64642	Human highly expre
74	8	40.0	8	1	AAH46942	Human ubiquitously
75	8	40.0	8	1	AAH44694	Human highly expre
76	8	40.0	8	1	AAH64130	Human MTR1 intron8
77	8	40.0	8	1	AAH63883	Human normal hepat
78	8	40.0	8	1	AAH64694	Yeast NORF gene SA
79	8	40.0	8	1	AAH20566	Yeast NORF gene SA
80	8	40.0	8	1	AAH06210	Yeast NORF gene SA
81	8	40.0	8	1	ABA06210	Yeast NORF gene SA
82	8	40.0	8	1	AAF41678	Yeast NORF gene SA
83	8	40.0	8	1	AAF35913	Yeast NORF gene SA
84	8	40.0	8	1	AAF73941	Yeast NORF gene SA
85	8	40.0	8	1	AAF39304	Yeast NORF gene SA
86	8	40.0	8	1	AAF37464	Yeast NORF gene SA
87	8	40.0	8	1	AAF40963	Primer #18 used to
88	8	40.0	8	1	AAD25091	Human AKR1B1 gene
89	8	40.0	8	1	AAD25091	Human SA homologue
90	8	40.0	8	1	ABL01199	Colony stimulating
91	8	40.0	8	1	AAS98855	Human ribosomal pr
92	8	40.0	8	1	ABK66385	Human ribosomal pr
93	8	40.0	8	1	ABV78317	Transcript tag DNA
94	8	40.0	8	1	ABV78363	Primer extension o
95	8	40.0	8	1	AAF84855	Interleukin 5 (IL5
96	8	40.0	8	1	ABK23667	Human PLAU gene, p
97	8	40.0	8	1	ABL57211	Human PLAU gene, p
98	8	40.0	8	1	ADH75063	Photodamage detect
99	8	40.0	8	1	ADM77078	Photodamage marker

ALIGNMENTS

RESULT 1
AAA64908

OM nucleic - nucleic search, using sw model

Copyright (c) 1993 - 2004 Compugen Ltd.

GenCore version 5.1.6

Run on: November 15, 2004, 08:23:31 ; Search time 0.001 Seconds
                                              (without alignments)
                                              20.560 Million cell updates/sec

Title: US-10-070-789-8
Perfect score: 20
Sequence: 1 taggacttgtccaacctttc 20

Scoring table: IDENTITY_NUC
                Gapop 10.0 , Gapext 0.5

Searched: 51 seqs, 514 residues

Total number of hits satisfying chosen parameters: 102

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 53 summaries

Database :   fetchrge8.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	DB ID	Description
1	20	100.0	20	1	AR103288	ACCESSION:AR103288
2	10	50.0	11	1	AX624749	ACCESSION:AX624749
3	10	50.0	11	1	AX625581	ACCESSION:AX625581
4	10	50.0	11	1	AX632170	ACCESSION:AX632170
5	9.4	47.0	11	1	CQ832708	ACCESSION:CQ832708
6	8.4	42.0	10	1	AR004345	ACCESSION:AR004345
7	8.4	42.0	10	1	AR004345	ACCESSION:AR004345
8	8.4	42.0	10	1	AR006836	ACCESSION:AR006836
9	8.4	42.0	10	1	AR006836	ACCESSION:AR006836
10	8.4	42.0	10	1	AR227862	ACCESSION:AR227862
11	8.4	42.0	10	1	AR303457	ACCESSION:AR303457
12	8.4	42.0	10	1	AR303598	ACCESSION:AR303598
13	8.4	42.0	10	1	AR303626	ACCESSION:AR303626
14	8.4	42.0	10	1	AX301603	ACCESSION:AX301603
15	8.4	42.0	10	1	BD086244	ACCESSION:BD086244
16	8.4	42.0	10	1	BD166548	ACCESSION:BD166548
17	8.4	42.0	10	1	BD166781	ACCESSION:BD166781
18	8	40.0	8	1	AX687084	ACCESSION:AX687084
19	8	40.0	8	1	AX687085	ACCESSION:AX687085
20	8	40.0	9	1	AX497971	ACCESSION:AX497971
21	8	40.0	10	1	AR000247	ACCESSION:AR000247
22	8	40.0	10	1	AR150602	ACCESSION:AR150602
23	8	40.0	10	1	BD240441	ACCESSION:BD240441
24	8	40.0	10	1	BD240561	ACCESSION:BD240561
25	8	40.0	10	1	E27852	ACCESSION:E27852
26	8	40.0	10	1	E27855	ACCESSION:E27855
27	8	40.0	10	1	E54835	ACCESSION:E54835
28	8	40.0	10	1	I83580	ACCESSION:I83580
29	8	40.0	10	1	I88948	ACCESSION:I88948
30	8	40.0	10	1	I88948	ACCESSION:I88948
31	8	40.0	10	1	AR200483	ACCESSION:AR200483
32	8	40.0	10	1	AR303539	ACCESSION:AR303539
33	8	40.0	10	1	AR371285	ACCESSION:AR371285
34	8	40.0	10	1	AR392565	ACCESSION:AR392565
35	8	40.0	10	1	AR489506	ACCESSION:AR489506
36	8	40.0	10	1	AR491117	ACCESSION:AR491117
37	8	40.0	10	1	AX113035	ACCESSION:AX113035
38	8	40.0	10	1	AX152807	ACCESSION:AX152807
39	8	40.0	10	1	AX152808	ACCESSION:AX152808
40	8	40.0	10	1	AX152809	ACCESSION:AX152809
41	8	40.0	10	1	AX153055	ACCESSION:AX153055
42	8	40.0	10	1	AX153567	ACCESSION:AX153567
43	8	40.0	10	1	AX153619	ACCESSION:AX153619
44	8	40.0	10	1	AX301314	ACCESSION:AX301314
45	8	40.0	10	1	AX301580	ACCESSION:AX301580
46	8	40.0	10	1	BD144707	ACCESSION:BD144707
47	8	40.0	10	1	BD161206	ACCESSION:BD161206
48	8	40.0	10	1	BD161252	ACCESSION:BD161252
49	7.4	37.0	10	1	CQ759123	ACCESSION:CQ759123
50	7.4	37.0	9	1	AX668629	ACCESSION:AX668629
51	7.4	37.0	9	1	AX668630	ACCESSION:AX668630
52	7.4	37.0	9	1	AX668813	ACCESSION:AX668813
53	7.4	37.0	9	1	AX668814	ACCESSION:AX668814

ALIGNMENTS

RESULT 1
AR103288

LOCUS   AR103288   20 bp   DNA   linear   PAT 14-FEB-2001
DEFINITION Sequence 8 from patent US 6087173.
ACCESSION   AR103288
VERSION   AR103288.1 GI:12814876
KEYWORDS   .
SOURCE   Unknown.
  ORGANISM Unknown.
            Unclassified.
REFERENCE   1 (bases 1 to 20)
  AUTHORS   Bennett,C.Frank, Ackermann,E.J. and Cowsert,L.M.
  TITLE   Antisense modulation of X-linked inhibitor of apoptosis expression
  JOURNAL   Patent: US 6087173-A 8 11-JUL-2000;
FEATURES   Location/Qualifiers
     source   1..20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

Query Match   100.0%; Score 20; DB 1; Length 20;
Best Local Similarity   100.0%;
Matches   20; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 TAGGACTTGTCCAACCTTTC 20
              ||||||||||||||||||||
Db   1 TAGGACTTGTCCAACCTTTC 20

RESULT 2
AX624749/c

LOCUS   AX624749   11 bp   DNA   linear   PAT 21-FEB-2003
DEFINITION Sequence 1790 from Patent WO02053774.
ACCESSION   AX624749
VERSION   AX624749.1 GI:28452690
KEYWORDS   .
SOURCE   Homo sapiens (human)
  ORGANISM Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Petersohn,D., Conradt,M. and Hofmann,K.
  TITLE   Method for determining homeostasis of the skin
  JOURNAL   Patent: WO 02053774-A 1790 11-JUL-2002;
            Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES   Location/Qualifiers
     source   1..11
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"

OM nucleic - nucleic search, using sw model

Run on: November 15, 2004, 08:29:17 ; Search time 0.001 seconds
                                          (without alignments)
           Copyright (c) 1993 - 2004 Compugen Ltd.   13.160 Million cell updates/sec
           GenCore version 5.1.6

Title: US-10-070-789-8
Perfect score: 20
Sequence: 1 taggactgtgtccacctttc 20

Scoring table: IDENTITY NUC
                Gapop 10.0 , Gapext 0.5

Searched: 34 seqs, 329 residues

Total number of hits satisfying chosen parameters: 68

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
                 Maximum Match 100%
                 Listing first 34 summaries

Database :   fetchrnpb8.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Match Length	DB	ID	Description
1	12.4	62.0	15	1	US-10-698-689-126	Sequence 126, Appl
2	8.4	42.0	10	1	US-10-055-713-35	Sequence 35, Appl
3	8.4	42.0	10	1	US-10-055-711-39	Sequence 39, Appl
4	8.4	42.0	10	1	US-10-418-552-25	Sequence 25, Appl
5	8.4	42.0	10	1	US-10-293-222-317	Sequence 317, Appl
6	8.4	42.0	10	1	US-10-650-454-40	Sequence 40, Appl
7	8.4	42.0	10	1	US-10-470-180-35	Sequence 35, Appl
8	8.4	42.0	8	1	US-09-910-469-5	Sequence 5, Appli
9	8.4	42.0	10	1	US-09-910-469-6	Sequence 6, Appli
10	8.4	42.0	10	1	US-10-330-627-1482	Sequence 1482, Ap
11	8.0	40.0	10	1	US-09-955-410-22	Sequence 22, Appl
12	8.0	40.0	10	1	US-09-983-210-26	Sequence 26, Appl
13	8.0	40.0	10	1	US-10-033-145-1979	Sequence 1979, Ap
14	8.0	40.0	10	1	US-10-033-145-1859	Sequence 1859, Ap
15	8.0	40.0	10	1	US-10-330-627-722	Sequence 722, App
16	8.0	40.0	10	1	US-10-330-627-723	Sequence 723, App
17	8.0	40.0	10	1	US-10-330-627-724	Sequence 724, App
18	8.0	40.0	10	1	US-10-330-627-970	Sequence 970, App
19	8.0	40.0	10	1	US-10-330-627-1482	Sequence 1482, Ap
20	8.0	40.0	10	1	US-10-154-890-22	Sequence 22, Appl
21	8.0	40.0	10	1	US-10-293-222-28	Sequence 28, Appl
22	8.0	40.0	10	1	US-10-293-222-294	Sequence 294, App
23	7.4	37.0	10	1	US-09-989-789-2078	Sequence 2078, Ap
24	7.4	37.0	10	1	US-09-989-789-2079	Sequence 2079, Ap
25	7.4	37.0	9	1	US-09-989-789-2262	Sequence 2262, Ap
26	7.4	37.0	9	1	US-09-989-789-2263	Sequence 2263, Ap
27	7.4	37.0	9	1	US-09-990-186-2079	Sequence 2079, Ap
28	7.4	37.0	9	1	US-09-990-186-2079	Sequence 2079, Ap
29	7.4	37.0	9	1	US-09-990-186-2262	Sequence 2262, Ap
30	7.4	37.0	9	1	US-09-990-186-2263	Sequence 2263, Ap
31	7.4	37.0	9	1	US-09-990-186-2078	Sequence 2078, Ap
32	7.4	37.0	9	1	US-09-989-994-2078	Sequence 2078, Ap
33	7.4	37.0	9	1	US-09-989-994-2079	Sequence 2079, Ap
34	7.4	37.0	9	1	US-09-989-994-2262	Sequence 2262, Ap

ALIGNMENTS

RESULT 1
US-10-698-689-126

; Sequence 126, Application US/10698689
; Publication No. US20040186071A1
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Cowsert, Lex M.
; APPLICANT: Malik, Leila
; APPLICANT: Siwkowski, Andrew
; APPLICANT: Eldrup, Anne B.
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD40 EXPRESSION
; FILE REFERENCE: ISIS-5315
; CURRENT APPLICATION NUMBER: US/10/698,689
; CURRENT FILING DATE: 2003-10-31
; PRIOR APPLICATION NUMBER: PCT/US03/31166
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 10/261,382
; PRIOR FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: US 09/067,638
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: US 60/081,483
; PRIOR FILING DATE: 1998-04-13
; NUMBER OF SEQ ID NOS: 248
; SOFTWARE: Patentin version 3.2
;
; SEQ ID NO 126
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-698-689-126

  Query Match   62.0%; Score 12.4; DB 1; Length 15;
  Best Local Similarity   92.9%; Pred. No. 0.53;
  Matches   13; Conservative   0; Mismatches   1; Indels   0; Gaps   0;

Qy   6 CTTGTGTCCACCTTTT 19
              ||||| ||||||||||
Db   2 CTTGACCACCTTTT 15

RESULT 2
US-10-055-713-35/c

; Sequence 35, Application US/10055713
; Publication No. US20030044957A1
; GENERAL INFORMATION:
; APPLICANT: LI, Guofu
; APPLICANT: JAMIESON, Andrew
; TITLE OF INVENTION: ZINC FINGER PROTEINS FOR DNA BINDING AND GENE
; TITLE OF INVENTION: REGULATION IN PLANTS
; FILE REFERENCE: 8325-0026 / S26-US1
; CURRENT APPLICATION NUMBER: US/10/055,713
; CURRENT FILING DATE: 2002-05-17
; PRIOR APPLICATION NUMBER: 60/263,445
; PRIOR FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: 60/290,716
; PRIOR FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: Patentin Ver. 2.0
;
; SEQ ID NO 35
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: ZFP 1 target sequence
US-10-055-713-35

Qy   11 CCACCTTT 18
               ||| |||||
Db   8 CCAGCTTT 1

RESULT 3
LOCUS   CF339699/c   8 bp   mRNA   linear   EST 18-AUG-2003
DEFINITION RCL1-05-K22.g1 Regenerated callus lambda phage cDNA library (RCL1)
            Oryza sativa (japonica cultivar-group) cDNA clone RCL1--05-K22,
            mRNA sequence.
ACCESSION   CF339699
VERSION   CF339699.1 GI:33827769
KEYWORDS   EST.
SOURCE   Oryza sativa (japonica cultivar-group)
ORGANISM   Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1 (bases 1 to 8)
AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE   Large-scale Sequencing Analysis of Rice ESTs
JOURNAL   Unpublished (2003)
COMMENT   Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, Myongji University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES   Location/Qualifiers
     source   1..8
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="RCL1--05-K22"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli SOLR"
                     /clone_lib="Regenerated callus lambda phage cDNA library
                     (RCL1)"
                     /note="Vector: pBluescript SK(+); Site_1: SstI; Site_2:
                     XhoI; cDNA was inserted into lamda Uni-ZAP XR vector at 5'
                     end with SstI and 3' end with XhoI site. Callus was
                     induced on 2N6 media for 30 days and cultured for 36hrs on
                     regenerated media"

Query Match   32.0%; Score 6.4; DB 1; Length 8;
Best Local Similarity   87.5%; Pred. No. 0;
Matches   7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy   11 CCACCTTT 18
               ||| |||||
Db   8 CCAGCTTT 1

RESULT 4
LOCUS   CF340204   8 bp   mRNA   linear   EST 18-AUG-2003
DEFINITION RCL1-07-E15.g1 Regenerated callus lambda phage cDNA library (RCL1)
            Oryza sativa (japonica cultivar-group) cDNA clone RCL1--07-E15,
            mRNA sequence.
ACCESSION   CF340204
VERSION   CF340204.1 GI:33828768
KEYWORDS   EST.
SOURCE   Oryza sativa (japonica cultivar-group)
ORGANISM   Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1 (bases 1 to 8)
AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE   Large-scale Sequencing Analysis of Rice ESTs
JOURNAL   Unpublished (2003)
COMMENT   Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, Myongji University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES   Location/Qualifiers
     source   1..8
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="RCL1--07-E15"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli SOLR"
                     /clone_lib="Regenerated callus lambda phage cDNA library
                     (RCL1)"
                     /note="Vector: pBluescript SK(+); Site_1: SstI; Site_2:
                     XhoI; cDNA was inserted into lamda Uni-ZAP XR vector at 5'
                     end with SstI and 3' end with XhoI site. Callus was
                     induced on 2N6 media for 30 days and cultured for 36hrs on
                     regenerated media"

Query Match   32.0%; Score 6.4; DB 1; Length 8;
Best Local Similarity   87.5%; Pred. No. 0;
Matches   7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy   11 CCACCTTT 18
               ||| |||||
Db   8 CCAGCTTT 1

Search completed: November 15, 2004, 08:31:01
Job time : 0.001 secs

OM nucleic - nucleic search, using sw model

Run on: November 15, 2004, 08:27:34 ; Search time 0.001 Seconds
                                             (without alignments)
                                             14.400 Million cell updates/sec

                         GenCore version 5.1.6
                         Copyright (c) 1993 - 2004 Compugen Ltd.

Title: US-10-070-789-8
Perfect score: 20
Sequence: 1 taggactgtgtccacctttc 20
Scoring table: IDENTITY_NUC
                  Gapop 10.0 , Gapext 0.5
Searched: 37 seqs, 360 residues
Total number of hits satisfying chosen parameters: 74
Minimum DB seq length: 8
Maximum DB seq length: 50
Post-processing: Minimum Match 0%
                  Maximum Match 100%
                  Listing first 39 summaries
Database :   fetchrni8.seq:*

      Pred. No. is the number of results predicted by chance to have a
      score greater than or equal to the score of the result being printed,
      and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	20	100.0	20	1	US-09-392-580-8	Sequence 8, Appli
2	8.4	42.0	10	1	US-08-460-806-27	Sequence 27, Appli
3	8.4	42.0	10	1	US-08-460-806-27	Sequence 27, Appli
4	8.4	42.0	10	1	US-08-325-630-27	Sequence 27, Appli
5	8.4	42.0	10	1	US-08-325-630-27	Sequence 27, Appl
6	8.4	42.0	10	1	US-08-388-353-191	Sequence 191, App
7	8.4	42.0	10	1	US-08-388-353-191	Sequence 191, App
8	8.4	42.0	10	1	US-08-388-353-278	Sequence 278, App
9	8.4	42.0	10	1	US-08-488-551B-191	Sequence 191, Appl
10	8.4	42.0	10	1	US-08-488-551B-278	Sequence 278, App
11	8.4	42.0	10	1	US-09-008-303-3	Sequence 3, Appli
12	8.4	42.0	10	1	US-09-008-303-3	Sequence 3, Appli
13	8.4	42.0	10	1	US-09-395-861-1	Sequence 1, Appli
14	8.4	42.0	10	1	US-09-508-753B-182	Sequence 182, App
15	8.4	42.0	10	1	US-09-508-753B-323	Sequence 323, App
16	8.4	42.0	10	1	US-09-508-753B-351	Sequence 351, App
17	8	40.0	8	1	US-08-859-954-208	Sequence 208, App
18	8	40.0	10	1	US-08-859-954-230	Sequence 230, App
19	8	40.0	10	1	US-08-859-954-540	Sequence 540, App
20	8	40.0	10	1	US-08-686-116A-45	Sequence 45, Appl
21	8	40.0	10	1	US-08-686-113A-52	Sequence 52, Appl
22	8	40.0	10	1	US-08-847-108-45	Sequence 45, Appl
23	8	40.0	10	1	US-08-847-095A-45	Sequence 45, Appli
24	8	40.0	10	1	US-08-088-661F-15	Sequence 15, Appl
25	8	40.0	10	1	US-08-150-156A-26	Sequence 26, Appli
26	8	40.0	10	1	US-08-088-591B-22	Sequence 22, Appl
27	8	40.0	10	1	US-08-686-114B-52	Sequence 52, Appl
28	8	40.0	10	1	US-09-508-753B-264	Sequence 264, App
29	8	40.0	10	1	US-09-508-753B-330	Sequence 330, App
30	8	40.0	10	1	US-09-337-304-52	Sequence 52, Appl
31	8	40.0	10	1	US-08-468-719A-22	Sequence 22, Appl
32	8	40.0	10	1	US-08-462-977B-22	Sequence 22, Appl
33	7	35.0	8	1	US-08-662-963-3	Sequence 3, Appli
34	7	35.0	8	1	US-08-662-963-10	Sequence 10, Appl
35	7	35.0	8	1	US-08-662-963-16	Sequence 16, Appl
36	7	35.0	8	1	US-08-662-963-19	Sequence 19, Appl
37	7	35.0	8	1	US-08-859-954-125	Sequence 125, App
38	7	35.0	8	1	US-08-859-954-245	Sequence 245, App
39	7	35.0	8	1	US-08-859-954-384	Sequence 384, App

ALIGNMENTS

RESULT 1
US-09-392-580-8
; Sequence 8, Application US/09392580
; Patent No. 6087173
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Elizabeth J. Ackerman
; APPLICANT: Lex M. Cowsert
; TITLE OF INVENTION: ANTISENSE MODULATION OF X-LINKED INHIBITOR OF APOPTOSIS EXPRESSIO
; FILE REFERENCE: RTS-0072
; CURRENT APPLICATION NUMBER: US/09/392,580
; CURRENT FILING DATE: 1999-09-09
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-392-580-8

Query Match   100.0%; Score 20; DB 1; Length 20;
Best Local Similarity   100.0%;
Matches   20; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 TAGGACTTGTCCACCTTTTC 20
              ||||||||||||||||||||
Db   1 TAGGACTTGTCCACCTTTTC 20

RESULT 2
US-08-460-806-27
; Sequence 27, Application US/08460806
; Patent No. 5747241
; GENERAL INFORMATION:
; APPLICANT: MIYAMURA, TATSUO
; APPLICANT: SAITO, IZUMU
; APPLICANT: HARADA, SHIZUKO
; APPLICANT: HONDA, YOSHIKAZU
; TITLE OF INVENTION: DIAGNOSTIC REAGENT FOR HEPATITIS C
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; ADDRESSEE: P.C.
; STREET: 1755 S. Jefferson Davis Highway, Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/460,806
; FILING DATE: 02-JUN-1995
; PRIOR APPLICATION DATA:
; CLASSIFICATION: 435
; APPLICATION NUMBER: US/08/325,630
; FILING DATE: 19-OCT-1994
; APPLICATION NUMBER: US 07/956,993

```
Set      Items    Description
S1        6121    (X-LINKED INHIBITOR OF APOPTOSIS) OR XIAP OR HIAP-1 OR HILP
                  OR (X-LINKED IAP) OR MIHA
S2      257315    ANTISENSE OR RIBOZYME OR TRIPLEX OR SIRNA OR RNAI OR (SHORT
                  INTERFER? RNA) OR (RNA INTERFER?)
S3    10136532    CANCER? OR TUMOR? OR TUMOUR? OR CARCINOMA?
S4     1886463    INFLAMMATORY OR INFLAMMATION
S5        1147    (FOLLICULAR ATRESIA?) OR (ATRESIA? FOLLICULAR)
S6         515    S1 AND S2
S7         436    S6 AND S3
S8     3487542    6 AND S3 OR S4 OR S5
S9     1888026    S6 AND S3 OR S4 OR S5
S10         26    S6 AND S4
S11          2    S6 AND S5
S12          0    9 RD
S13    3487542    6 AND S3 OR S4 OR S5
S14    1888026    S6 AND S3 OR S4 OR S5
S15        436    S6 AND S3
S16        165    RD (unique items)
S17         10    S16 NOT PY>2000
```

JOURNAL REGION: USA
JOURNAL SUBJECT: Business; General News
? S S16 NOT PY>2000
Processing
Processing
Processed 10 of 18 files ...
Processing
>>>One or more prefixes are unsupported
>>> or undefined in one or more files.
Processing
Processing
Completed processing all files
            165   S16
         94675125 PY>2000
     S17   10 S16 NOT PY>2000
? T S17/MEDIUM,K/ALL
>>>KWIC option is not available in file(s): 398, 399

 17/K/1   (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)

0013237922   BIOSIS NO.: 200100409761
**Gene therapy that inhibits nuclear translocation of nuclear factor kappaB
   results in tumor necrosis factor alpha-induced apoptosis of human
   synovial fibroblasts**

AUTHOR: Zhang Huang-Ge; Huang Ning; Liu Di; Bilbao Lupita; Zhang Xiaowu;
   Yang Pingar; Zhou Tong; Curiel David T; Mountz John D (Reprint)
AUTHOR ADDRESS: Department of Medicine, Division of Clinical Immunology and
   Rheumatology, The University of Alabama at Birmingham, 701 South 19th
   Street, LHRB 473, Birmingham, AL, 35294, USA**USA

**Gene therapy that inhibits nuclear translocation of nuclear factor kappaB
   results in tumor necrosis factor alpha-induced apoptosis of human
   synovial fibroblasts**

ABSTRACT: Objective. **Tumor** necrosis factor alpha (TNFalpha) increases the
   survival and proliferation of human rheumatoid arthritis (RA) cell...

...factor kappaB (IkappaB) dominant-negative adenovirus (AdCMVIkappaB-DN)
   and an X-linked inhibitor of apoptosis (**XIAP**) **antisense** adenovirus
   (AdCMVXIAP-AS). Primary RA synovial fibroblast (RASF) cell lines were
   transfected in vitro, and...

...TNFalpha. There was no apoptosis after treatment with AdCMVIkappaB-DN in
   the absence of TNFalpha. **XIAP** is an inhibitor of apoptosis which was
   up-regulated by TNFalpha, and this up-regulation...

...greatly enhances apoptosis due to inhibition of an NF-kappaB-mediated
   antiapoptosis signaling pathway, and **XIAP** is a TNFalpha-inducible
   specific inhibitor of apoptosis in RA synovial cell lines. This and...
DESCRIPTORS:

17/K/2   (Item 2 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0012897193   BIOSIS NO.: 200100069032
Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated
  apoptosis by down-regulating FLIP-L expression
AUTHOR: Kinoshita Hirokazu; Yoshikawa Hideshi; Shiki Kazuhiko; Hamada
  Yoshiki; Nakajima Yasuo; Tasaka Kachio (Reprint)
AUTHOR ADDRESS: Department of Parasitology and Immunology, Yamanashi
  Medical University, 1110 Shimokato, Tamaho-cho, Yamanashi, 409-3898,
  Japan**Japan
JOURNAL: International Journal of Cancer 88 (6): p986-991 15 December,
2000 2000
MEDIUM: print
ISSN: 0020-7136
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: escape from Fas/CD95-mediated apoptosis induced by
  immunosurveillance(NK cells and T cells) in **tumor** cells are correlated
  to **tumorigenicity** . Human osteosarcoma cell MG-63 constitutively
  expressed cell surface Fas antigen but was resistant to...
...form(FLIP-L), which was a novel anti-apoptotic protein and had a potency
  of **tumorigenicity** . CDDP down-regulated FLIP-L in a time-dependent
  manner in MG-63 cells but did not influence expression of other
  anti-apoptotic molecules such as **XIAP** , c-IAP-1, c-IAP-2, FADD or
  pro-caspase-8. Moreover, **antisense** oligonucleotide to FLIP-L confirmed
  that down-regulation of FLIP-L induced sensitization to Fas...
DESCRIPTORS:
  ...MAJOR CONCEPTS: **Tumor** Biology
  CHEMICALS & BIOCHEMICALS: ... **XIAP** ;

17/K/3   (Item 3 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0012810857   BIOSIS NO.: 200000529170
Down-regulation of X-linked inhibitor of apoptosis protein induces
  apoptosis in chemoresistant human ovarian cancer cells
AUTHOR: Sasaki Hiromasa; Sheng YingLun; Kotsuji Fumikazu; Tsang Benjamin K
  (Reprint)
AUTHOR ADDRESS: Loeb Health Research Institute, 725 Parkdale Avenue,
  Ottawa, Ontario, K1Y 4E9: btsang@lri.ca, Canada**Canada
JOURNAL: Cancer Research 60 (20): p5659-5666 October 15, 2000 2000
MEDIUM: print
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Down-regulation of X-linked inhibitor of apoptosis protein induces
  apoptosis in chemoresistant human ovarian cancer cells

ABSTRACT: Cisplatin-centered chemotherapy is a key treatment for ovarian **cancer** , but resistance to chemotherapeutic agents remains a major cause of treatment failure. Multiple factors are...

...of this chemoresistance. Although it has been demonstrated that X-linked inhibitor of apoptosis protein (**Xiap**) prevents apoptosis by inhibiting effector caspases, if and how it is important in chemoresistance in ovarian **cancer** has not been studied. The effects of **Xiap** down-regulation and/or restoration of wild type p53 by recombinant adenovirus infection were examined on four ovarian epithelial **cancer** cell lines (C13*, A2780-s (wild type p53), A2780-cp (mutant p53), and SKOV3 (null p53)). Apoptosis and protein expression (e.g., **Xiap** , caspase-3, p53, MDM2, and p21wafl) were assessed by Hoechst 33258 stain and Western blot, respectively. We demonstrated that **Xiap** down-regulation following adenoviral **antisense** expression induces apoptosis in the wild-type p53 cells, but not in the mutated or null cells. **Xiap** down-regulation resulted in caspase-3 activation, caspase-mediated MDM2 processing, and p53 accumulation. Restoration...

...type p53 in the p53-mutated or -null cells significantly enhanced the proapoptotic effect of **Xiap** **antisense** expression. Down-regulation of **Xiap** induced apoptosis in chemoresistant ovarian **cancer** cells, a process dependent on p53 status.

DESCRIPTORS:

...MAJOR CONCEPTS: **Tumor** Biology

...ORGANISMS: chemoresistance, human ovarian **cancer** cell line, in-vitro model system, mutant p53 gene expression...

...chemoresistance, human ovarian **cancer** cell line, in-vitro model system, wild type p53 gene expression...

...chemoresistance, human ovarian **cancer** cell line, in-vitro model system, wild type p53 gene expression...

...chemoresistance, human ovarian **cancer** cell line, in-vitro model system, null p53 gene expression

CHEMICALS & BIOCHEMICALS: ...X-linked inhibitor of apoptosis downregulation role, caspase-mediated processing, **tumor** cell expression...

... **antisense** transfer-mediated downregulation, chemoresistant **tumor** cell apoptosis induction, recombinant adenovirus-mediated **antisense** transfer, **tumor** cell expression...

...X-linked inhibitor of apoptosis protein-induced **tumor** cell expression ...

...antineoplastic-drug, **tumor** cell resistance...

...X-linked inhibitor of apoptosis downregulation role, **tumor** cell accumulation

17/K/4 **(Item 4 from file: 5)**

0012731647 BIOSIS NO.: 200000449960

**Translational upregulation of X-linked inhibitor of apoptosis (XIAP)
  increases resistance to radiation induced cell death**

AUTHOR: Holcik Martin; Yeh Chiaoli; Korneluk Robert G (Reprint); Chow Terry
AUTHOR ADDRESS: Molecular Genetics, Research Institute, Children's Hospital
  of Eastern Ontario, 401 Smyth Road, Ottawa, Ontario, K1H 8L1, Canada**
  Canada

ABSTRACT: Inhibitory regulators of apoptosis play a critical role in the
  responsiveness of **tumour** cells to cytotoxic agents. The X-linked
  inhibitor of apoptosis protein (**XIAP**) is a member of a novel family of
  Inhibitor of Apoptosis (IAP) proteins. Here we show that acute low dose
  ionizing irradiation results in the translational upregulation of **XIAP**
  that correlates with an increased resistance to radiation in non-small
  cell lung **carcinoma** . This upregulation is mediated by an internal
  ribosome binding mechanism via an IRES element located within a **XIAP** 5'
  UTR. Transient overexpression of **XIAP** rendered human **carcinoma** cells
  resistant to low dose gamma-irradiation. By contrast, the **antisense**
  targeting of **XIAP** resulted in increased cell death following
  irradiation advocating a distinct role for **XIAP** in radiation resistant
  phenotype of human **cancers** .
DESCRIPTORS:
  ...MAJOR CONCEPTS: **Tumor** Biology
  DISEASES: **cancer** --...

...non-small cell lung **carcinoma** --
  ...MESH TERMS: **Carcinoma** , Non-Small-Cell Lung (MeSH
  CHEMICALS & BIOCHEMICALS: ... **X-linked inhibitor of apoptosis** ...

... **antisense** targeting, translation upregulation...

... **tumor** cell responsiveness

 17/K/5   **(Item 5 from file: 5)**

**Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by
  down-regulating Fas-associated death domain-like interleukin 1-converting
  enzyme inhibitory protein expression**
AUTHOR: Fulda Simone; Meyer Eric; Debatin Klaus-Michael (Reprint)
AUTHOR ADDRESS: University Children's Hospital, Prittwitzstrasse 43,
  D-89075, Ulm, Germany**Germany

RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: both molecules have a high turnover rate. Selective
down-regulation of FLIP expression by FLIP **antisense** oligonucleotides
sensitized for CD95-induced apoptosis. Reduction of FLIP levels resulted
in undetectable amounts of...

...sensitized for subsequent CD95 stimulation compared with cells without
pretreatment. CHX or ActD also reduced **XIAP** expression and similarly
sensitized for **tumor** necrosis factor-related apoptosis-inducing ligand-
or **tumor** necrosis factor-alpha-induced apoptosis. Because blockade of
death receptor triggering by FLIP overexpression has recently been
implicated in **tumorigenesis** and treatment resistance in vivo,
strategies to inhibit FLIP expression, e.g., by metabolic inhibitors, may
prove to be a useful complementary tool for the treatment of **cancer** .
DESCRIPTORS:
  ...MAJOR CONCEPTS: **Tumor** Biology
  CHEMICALS & BIOCHEMICALS: ...metabolic inhibitor drug sensitization,
    tumor cell apoptosis induction...

...metabolic inhibitor drug-induced downregulation, **tumor** cell,
    expression...

17/K/6   (Item 6 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0012599835   BIOSIS NO.: 200000318148
Apoptosis and chemoresistance in human ovarian cancer : **Is** Xiap **a**
  determinant?
AUTHOR: Li Julang; Sasaki Hiromasa; Sheng Ying Lun; Schneiderman Danielle;
  Xiao Chao Wu; Kotsuji Fumikazu; Tsang Benjamin K (Reprint)
AUTHOR ADDRESS: Department of Obstetrics and Gynaecology, Ottawa Hospital,
  1053 Carling Avenue, Civic Campus, Ottawa, ON, K1Y 4E9, Canada**Canada
JOURNAL: Biological Signals and Receptors   9 (2): p122-130 March-April,
2000 2000
MEDIUM: print
ISSN: 1422-4933
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Apoptosis and chemoresistance in human ovarian cancer : **Is** Xiap **a**
  determinant?

ABSTRACT: Cisplatin-induced apoptosis in epithelial ovarian **cancer** cells
  is in part a consequence of suppressed **Xiap** expression and upregulation
  of the Fas/FasL system. Changes in the expression of these 'cell...
...genes lead to activation of caspase-3, and cleavage of MDM2 and FAK.
  Failure of **cancer** cells to maintain a balance in the expression of
  these genes in favor of apoptotic cell death may be an important factor
  of chemoresistance. **Xiap** may be a novel target for gene therapy of
  human ovarian epithelial **cancer** and, dependent on P53 status,
  expression of **Xiap** **antisense** alone or in combination with wild-type
  P53 sense may offer a new approach for the treatment of the
  chemoresistant **cancer** .

DESCRIPTORS:
  DISEASES: ovarian **cancer** --

  17/K/7   **(Item 1 from file: 155)**
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

14387430   PMID: 10381630
  **Expression and biological activity of X-linked inhibitor of apoptosis (
  XIAP) in human malignant glioma.**
  Wagenknecht B; Glaser T; Naumann U; Kugler S; Isenmann S; Bahr M;
Korneluk R; Liston P; Weller M
  Laboratory of Molecular Neuro-Oncology, Hoppe-Seyler-Strasse 3, Germany.
  Cell death and differentiation (ENGLAND)   Apr 1999, 6 (4) p370-6,
ISSN 1350-9047   Journal Code: 9437445
  Document type: Journal Article
  Languages: ENGLISH
  Main Citation Owner: NLM
  Record type: Completed

  **Expression and biological activity of X-linked inhibitor of apoptosis (
  XIAP) in human malignant glioma.**
  ... via direct inhibition of caspases. Here, we report that human
malignant glioma cell lines express **XIAP** , HIAP-1 and HIAP-2 mRNA and
proteins. NAIP was not expressed. IAP proteins were...

  ... exposure to CD95L and a protein synthesis inhibitor, CHX, to acquire
sensitivity to apoptosis. Adenoviral **XIAP** gene transfer blocked caspase 8
and 3 processing in both cell lines in the absence of CHX. Apoptosis was
blocked in the absence and in the presence of CHX. However, **XIAP** failed
to block caspase 8 processing in LN-229 cells in the presence of CHX. There
was considerable overlap of the effects of **XIAP** on caspase processing
with those of BCL-2 and the viral caspase inhibitor crm-A...

  ... of these cells to apoptotic stimuli that directly target caspases,
including radiochemotherapy and immune-mediated **tumor** cell lysis.
  ; Adenoviridae--genetics--GE; Antigens, CD95--genetics--GE; **Antisense**
 Elements (Genetics); Caspases--metabolism--ME; Gene Transfer Techniques;
Neoplasm Proteins--genetics--GE; Proteins--genetics--GE; **Tumor** Cells,
Cultured--enzymology--EN;   **Tumor** Cells, Cultured--pathology--PA; **Tumor**
 Cells, Cultured--physiology--PH
  Chemical Name: Antigens, CD95; **Antisense** Elements (Genetics); IAP-like
protein, vertebrate; Neoplasm Proteins; Proteins; Caspases

  17/K/8   **(Item 1 from file: 399)**
DIALOG(R)File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.

  130137344   CA: 130(11)137344n   PATENT
  **XAF proteins interacting with IAPs (inhibitors of apoptosis proteins) and
the genes encoding them and their use in the therapeutic regulation of
apoptosis**
  INVENTOR(AUTHOR): Korneluk, Robert; Tamai, Katsuyuki; Liston, Peter;
Mackenzie, Alexander E.; Baird, Stephen
  LOCATION: Can.,
  ASSIGNEE: University of Ottawa

PATENT: European Pat. Appl. ; EP 892048 A2   DATE: 19990120
   APPLICATION: EP 98113003 (19980713) *US 52402 (19970714) *US 54491
(19970801) *US 56338 (19970818)
   PAGES: 101 pp.   CODEN: EPXXDW   LANGUAGE: English   CLASS: C12N-015/12A;
C12N-015/11B; C07K-014/47B; C12N-015/85B; C12N-005/10B; A01K-067/027B;
G01N-033/50B; A61K-038/17B; A61K-048/00B; C12Q-001/68B; C12P-021/08B
   DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL;
SE; MC; PT; IE; SI; LT; LV; FI; RO

   17/K/9   **(Item 2 from file: 399)**
DIALOG(R)File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.

   129197985   CA: 129(16)197985m   PATENT
   **Detection and modulation of protein inhibitors of apoptosis (IAPs) and
neuronal apoptosis-inhibiting protein (NAIP) for the diagnosis and
treatment of proliferative disease**
   INVENTOR(AUTHOR): Korneluk, Robert; MacKenzie, Alexander E.; Liston,
Peter; Baird, Stephen; Tsang, Benjamin; Pratt, Christine
   LOCATION: Can.,
   ASSIGNEE: University of Ottawa
   PATENT: PCT International ; WO 9835693 A2   DATE: 19980820
   APPLICATION: WO 98IB781 (19980213) *US 800929 (19970213)
   PAGES: 148 pp.   CODEN: PIXXD2   LANGUAGE: English   CLASS: A61K-038/17A;
A61K-031/70B; A61K-039/395B; C12N-015/11B; C12Q-001/68B; G01N-033/50B;
G01N-033/574B; A01K-067/027B; C12N-015/00B   DESIGNATED COUNTRIES: AL; AM;
AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB;
GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT;
LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK;
SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU;
TJ; TM   DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH
; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG;
CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

   17/K/10   **(Item 1 from file: 144)**
DIALOG(R)File 144:Pascal
(c) 2004 INIST/CNRS. All rts. reserv.

   14624714   PASCAL No.: 00-0295143
   **Gene therapy that inhibits nuclear translocation of nuclear factor KB
results in tumor necrosis factor alpha -induced apoptosis of human
synovial fibroblasts**
   ZHANG H G; NING HUANG; DI LIU; BILBAO L; XIAOWU ZHANG; YANG P; TONG ZHOU;
CURIEL D T; MOUNTZ J D
   University of Alabama at Birmingham, United States; Gene Therapy Program,
Birmingham, Alabama, United States; University of Alabama at Birmingham,
Birmingham, Alabama, United States; Veterans Administration Medical Center,
Birmingham, Alabama, United States
   Journal: Arthritis and rheumatism, 2000, 43 (5) 1094-1105
   Language: English

   **Gene therapy that inhibits nuclear translocation of nuclear factor KB
results in tumor necrosis factor alpha -induced apoptosis of human
synovial fibroblasts**

Objective. **Tumor** necrosis factor a (TNFa) increases the survival and proliferation of human rheumatoid arthritis (RA) cell...
... factor KB (IKB) dominant-negative adenovirus (AdCMVIKB-DN) and an X-linked inhibitor of apoptosis (**XIAP**) **antisense** adenovirus (AdCMVXIAP-AS). Primary RA synovial fibroblast (RASF) cell lines were transfected in vitro, and...

... was no apoptosis after treatment with AdCMVI kappa B-DN in the absence of TNFa. **XIAP** is an inhibitor of apoptosis which was up-regulated by TNFa, and this up-regulation...

... greatly enhances apoptosis due to inhibition of an NF-KB-mediated antiapoptosis signaling pathway, and **XIAP** is a TNFa-inducible specific inhibitor of apoptosis in RA synovial cell lines. This and...

English Descriptors: Rheumatoid arthritis; Treatment; Chemotherapy; Gene therapy; Mechanism of action; Inhibition; Translocation; Apoptosis; Cell death; **Tumor** necrosis factor alpha ; Fibroblast; Synovial membrane; In vitro; Human; Tissue culture; Chronic; Transcription factor NF...

French Descriptors: Polyarthrite rhumatoide; Traitement; Chimiotherapie; Therapie genique; Mecanisme action; Inhibition; Translocation; Apoptose; Mort cellulaire; Facteur necrose **tumorale** alpha ; Fibroblaste; Synoviale; In vitro; Homme; Culture tissu; Chronique; Facteur transcription NF kappa B

Spanish Descriptors: Poliartritis reumatoidea; Tratamiento; Quimioterapia; Terapia genica; Mecanismo accion; Inhibicion; Translocacion; Apoptosis; Muerte celular; Factor necrosis **tumoral** alpha ; Fibroblasto; Sinovial; In vitro; Hombre; Cultivo tejido; Cronico
?

```
18        6121    (X-LINKED INHIBITOR OF APOPTOSIS) OR XIAP OR HIAP-1 OR HILP
                  OR (X-LINKED IAP) OR MIHA
S19     257315    ANTISENSE OR RIBOZYME OR TRIPLEX OR SIRNA OR RNAI OR (SHORT
                  INTERFER? RNA) OR (RNA INTERFER?)
S20   10136532    CANCER? OR TUMOR? OR TUMOUR? OR CARCINOMA?
S21    1886463    INFLAMMATORY OR INFLAMMATION
S22       1147    (FOLLICULAR ATRESIA?) OR (ATRESIA? FOLLICULAR)
S23        515    S18 AND S19
S24        436    S23 AND S20
S25    3487542    6 AND S20 OR S21 OR S22
S26    1888026    S23 AND S20 OR S21 OR S22
S27         26    S23 AND S21
S28          2    S23 AND S22
S29          0    9 RD
S30    3487542    6 AND S20 OR S21 OR S22
S31    1888026    S23 AND S20 OR S21 OR S22
S32        436    S23 AND S20
S33        165    RD (unique items)
S34         10    S33 NOT PY>2000
```

```
Set      Items     Description
S1        6121     (X-LINKED INHIBITOR OF APOPTOSIS) OR XIAP OR HIAP-1 OR HILP
                   OR (X-LINKED IAP) OR MIHA
S2       257315    ANTISENSE OR RIBOZYME OR TRIPLEX OR SIRNA OR RNAI OR (SHORT
                   INTERFER? RNA) OR (RNA INTERFER?)
S3     10136532    CANCER? OR TUMOR? OR TUMOUR? OR CARCINOMA?
S4      1886463    INFLAMMATORY OR INFLAMMATION
S5        1147     (FOLLICULAR ATRESIA?) OR (ATRESIA? FOLLICULAR)
S6         515     S1 AND S2
S7         436     S6 AND S3
S8      3487542    6 AND S3 OR S4 OR S5
S9      1888026    S6 AND S3 OR S4 OR S5
S10         26     S6 AND S4
S11          2     S6 AND S5
S12          0     9 RD
S13     3487542    6 AND S3 OR S4 OR S5
S14     1888026    S6 AND S3 OR S4 OR S5
S15        436     S6 AND S3
S16        165     RD (unique items)
S17         10     S16 NOT PY>2000
S18       6121     (X-LINKED INHIBITOR OF APOPTOSIS) OR XIAP OR HIAP-1 OR HILP
                   OR (X-LINKED IAP) OR MIHA
S19      257315    ANTISENSE OR RIBOZYME OR TRIPLEX OR SIRNA OR RNAI OR (SHORT
                   INTERFER? RNA) OR (RNA INTERFER?)
S20    10136532    CANCER? OR TUMOR? OR TUMOUR? OR CARCINOMA?
S21     1886463    INFLAMMATORY OR INFLAMMATION
S22       1147     (FOLLICULAR ATRESIA?) OR (ATRESIA? FOLLICULAR)
S23        515     S18 AND S19
S24        436     S23 AND S20
S25     3487542    6 AND S20 OR S21 OR S22
S26     1888026    S23 AND S20 OR S21 OR S22
S27         26     S23 AND S21
S28          2     S23 AND S22
S29          0     9 RD
S30     3487542    6 AND S20 OR S21 OR S22
S31     1888026    S23 AND S20 OR S21 OR S22
S32        436     S23 AND S20
S33        165     RD (unique items)
S34         10     S33 NOT PY>2000
```

? T S27/MEDIUM,K/ALL
>>>KWIC option is not available in file(s): 398, 399

27/K/1 **(Item 1 from file: 5)**
DIALOG(R)File   5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0013914248   BIOSIS NO.: 200200507759
CD40 engagement enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation
AUTHOR: Bureau Fabrice (Reprint); Seumois Gregory; Jaspar Fabrice; Vanderplasschen Alain; Detry Bruno; Pastoret Paul-Pierre; Louis Renaud; Lekeux Pierre
AUTHOR ADDRESS: Department of Physiology, Faculty of Veterinary Medicine, University of Liege, Sart Tilman, Bat. B42, B-4000, Liege, Belgium** Belgium
JOURNAL: Journal of Allergy and Clinical Immunology 110 (3): p443-449
September, 2002 2002
MEDIUM: print
ISSN: 0091-6749
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

...**survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic** inflammation
...ABSTRACT: of the inhibitor of apoptosis protein (IAP) family, namely cellular (c)-IAP1, c-IAP2, and **XIAP** , and 2 antiapoptotic proteins of the Bcl-2 family, namely Bcl-xL and Bfl-1...

...staining with propidium iodide and FITC-conjugated annexin-V. c-IAP2 expression was inhibited with **antisense** oligonucleotides. Results: Freshly isolated eosinophils from healthy and asthmatic patients did not express CD40. Conversely...

...Inhibition of eosinophil apoptosis was accompanied by induction of c-IAP2 but not c-IAP1, **XIAP** , Bcl-xL, or Bfl-1/Al expression. **Antisense** knockdown of c-iap2 abolished CD40-induced enhancement of eosinophil survival. Sputum cells from asthmatic...

...through induction of c-IAP2 expression and suggest a role for this mechanism in allergic **inflammation** .
DESCRIPTORS:
  DISEASES: allergic **inflammation** --
  CHEMICALS & BIOCHEMICALS: ...X-inhibitor of apoptosis protein { **XIAP** };

27/K/2 **(Item 1 from file: 440)**
DIALOG(R)File 440:Current Contents Search(R)
(c) 2004 Inst for Sci Info. All rts. reserv.

19160771 Document Delivery Available: 0002235546
ISSN: 0021-9258
JOURNAL: JOURNAL OF BIOLOGICAL CHEMISTRY , 2004
  (TABLE OF CONTENTS RECORD)
  (The Complete Table of Contents now Available in Format 19)

...kappa B kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks
osteoclastogenesis and bone erosion in **inflammatory** arthritis.
Dai S; Hirayama T; Abbas S; Abu-Amer Y. Washington Univ, Dept
Orthoped Surg...

...000223554600075

P. 37982-37996. Post-transcriptional regulation of endothelial
nitric-oxide synthase by an overlapping **antisense** mRNA transcript.
Robb GB; Carson AR; Tai SC; Fish JE; Singh S; Yamada T;
Scherer...Geneva//Switzerland/. English. ARTICLE. 77 REFERENCES.
ABSTRACT AVAILABLE. Document Delivery no: 000223554600028

P. 37431-37435. **RNAi** -based analysis of CAP, Cbl, and CrkII function
in the regulation of GLUT4 by insulin...processing of HtrA2/Omi is
essential for induction of caspase-dependent cell death through
antagonizing **XIAP** . Seong YM; Choi JY; Park HJ; Kim KJ; Ahn
SG; Seong GH; Kim IK; Kang...

27/K/3 **(Item 2 from file: 440)**
DIALOG(R)File 440:Current Contents Search(R)
(c) 2004 Inst for Sci Info. All rts. reserv.

18293256 Document Delivery Available: 0002208704
ISSN: 0021-9258
JOURNAL: JOURNAL OF BIOLOGICAL CHEMISTRY , 2004
(TABLE OF CONTENTS RECORD)
(The Complete Table of Contents now Available in Format 19)

...AVAILABLE. Document Delivery no: 000220870400117

P. 18091-18097. In vivo chromatin remodeling events leading to
inflammatory gene transcription under diabetic conditions. Miao F;
Gonzalo IG; Lanting L; Natarajan R. City Hope...

...Determination of the role of the human RNase H1 in the pharmacology of
DNA-like **antisense** drugs. Wu HJ; Lima WF; Zhang H; Fan A; Sun
H; Crooke ST. ISIS Pharmaceut...DIABLO selectively reduces the
levels of c-IAP1 and c-IAP2 but not that of **XIAP** and livin in HeLa
cells. Yang QH; Du CY. Stowers Inst Med Res, 1000E 50th...

27/K/4 **(Item 3 from file: 440)**
DIALOG(R)File 440:Current Contents Search(R)
(c) 2004 Inst for Sci Info. All rts. reserv.

16540078 Document Delivery Available: 0001841087
ISSN: 1078-0432
JOURNAL: CLINICAL CANCER RESEARCH , 2003
(TABLE OF CONTENTS RECORD)
(The Complete Table of Contents now Available in Format 19)

...English. ARTICLE. 25 REFERENCES. ABSTRACT AVAILABLE. Document
Delivery no: 000184108700017

P. 2510-2519. Efficacy of **antisense** morpholino oligomer targeted to
c-myc in prostate cancer xenograft murine model and a phase...
AVAILABLE. Document Delivery no: 000184108700052

P. 2798-2806. The novel synthetic triterpenoid, CDDO-imidazolide,
    inhibits **inflammatory** response and tumor growth in vivo. Place
    AE; Suh N; Williams CR; Risingsong R; Honda...Bloomington//MN/.
    English. ARTICLE. 46 REFERENCES. ABSTRACT AVAILABLE. Document
    Delivery no: 000184108700055

P. 2826-2836. **Antisense** oligonucleotides targeting **XIAP** induce
    apoptosis and enhance chemotherapeutic activity against human lung
    cancer cells in vitro and in...

...Utrecht//Netherlands/. English. ARTICLE. 40 REFERENCES. ABSTRACT
    AVAILABLE. Document Delivery no: 000184108700058

P. 2856-2865. **Antisense** Bcl-xl down-regulation switches the response
    to topoisomerase I inhibition from senescence to apoptosis...

27/K/5   (Item 4 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)
(c) 2004 Inst for Sci Info. All rts. reserv.

14656002 Document Delivery Available: 000177936900015 References: 31
TITLE: CD40 engagement enhances eosinophil survival through induction of
    cellular inhibitor of apoptosis protein 2 expression: Possible
    involvement in allergic inflammation
AUTHOR(S): Bureau F (REPRINT); Seumois G; Jaspar F; Vanderplasschen A;
   Detry B; Pastoret PP; Louis R; Lekeux P
CORPORATE SOURCE: Univ Liege, Dept Physiol, Bat B42/B-4000 Liege//Belgium/
   (REPRINT); Univ Liege, Dept Physiol, /B-4000 Liege//Belgium/; Univ Liege,
   Dept Immunol Vaccinol, /B-4000 Liege//Belgium/; Univ Liege, Dept Pneumol,
   /B-4000 Liege//Belgium/
PUBLICATION TYPE: JOURNAL
PUBLICATION: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, V110, N3 (
   SEP), P443-449
GENUINE ARTICLE#: 592KM
PUBLISHER: MOSBY, INC, 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO
   63146-3318 USA
ISSN: 0091-6749
LANGUAGE: English   DOCUMENT TYPE: ARTICLE   (ABSTRACT AVAILABLE)

...**TITLE: survival through induction of cellular inhibitor of apoptosis**
    protein 2 expression: Possible involvement in allergic inflammation

...ABSTRACT: of the inhibitor of apoptosis protein (IAP) family, namely
cellular (c)-IAP1, c-IAP2, and **XIAP** , and 2 antiapoptotic proteins of the
Bcl-2 family, namely Bcl-x(L) and Bfl...

...staining with propidium iodide and FITC-conjugated annexin-V. c-IAP2
expression was inhibited with **antisense** oligonucleotides.

    Results: Freshly isolated eosinophils from healthy and asthmatic
patients did not express CD40. Conversely...

...Inhibition of eosinophil apoptosis was accompanied by induction of
c-IAP2 but not c-IAP1, **XIAP** , Bcl-x(L), or Bfl-1/A1 expression. **Antisense**
 knockdown of c-iap2 abolished CD40-induced enhancement of eosinophil
survival. Sputum cells from asthmatic...

...through induction of c-IAP2 expression and suggest a role for this
mechanism in allergic **inflammation** .

27/K/6   (Item 5 from file: 440)

      ...Div, /E Melbourne/Vic 3000/Australia/. English. ARTICLE. 33
      REFERENCES. ABSTRACT AVAILABLE

   P. 32077-32088. **Inflammatory** versus proliferative processes in
      epidermis - Tumor necrosis factor alpha induces K6b keratin
      synthesis through a...Dept Biomed Engn, /Memphis//TN/38152.
      English. ARTICLE. 50 REFERENCES. ABSTRACT AVAILABLE

   P. 31733-31738. **XIAP** regulates DNA damage-induced apoptosis
      downstream of caspase-9 cleavage. Datta R; ...D-35033
      Marburg//Germany/. English. ARTICLE. 58 REFERENCES. ABSTRACT
      AVAILABLE

   P. 32281-32288. Expression of **antisense** to integrin subunit beta(3)
      inhibits microvascular endothelial cell capillary tube formation in
      fibrin. Dallabrida...

27/K/7   (Item 1 from file: 34)

**Title: CD40 engagement enhances eosinophil survival through induction of
    cellular inhibitor of apoptosis protein 2 expression: Possible
    involvement in allergic** inflammation
Author(s): Bureau F (REPRINT) ; Seumois G; Jaspar F; Vanderplasschen A;
    Detry B; Pastoret PP; Louis R; Lekeux P
Corporate Source: Univ Liege,Fac Vet Med, Dept Physiol,Bat B42/B-4000
    Liege//Belgium/ (REPRINT); Univ Liege,Fac Vet Med, Dept Physiol,B-4000
    Liege//Belgium/; Univ Liege,Fac Vet Med, Dept Immunol Vaccinol,B-4000
    Liege//Belgium/; Univ Liege,Fac Med, Dept Pneumol,B-4000
    Liege//Belgium/

...**Title: survival through induction of cellular inhibitor of apoptosis
    protein 2 expression: Possible involvement in allergic** inflammation
...Abstract: of the inhibitor of apoptosis protein (IAP) family, namely

cellular (c)-IAP1, c-IAP2, and **XIAP** , and 2 antiapoptotic proteins of
the Bcl-2 family, namely Bcl-x(L) and Bfl...

...staining with propidium iodide and FITC-conjugated annexin-V. c-IAP2
expression was inhibited with **antisense** oligonucleotides.

Results: Freshly isolated eosinophils from healthy and asthmatic
patients did not express CD40. Conversely...

...Inhibition of eosinophil apoptosis was accompanied by induction of
c-IAP2 but not c-IAP1, **XIAP** , Bcl-x(L), or Bfl-1/A1 expression.
Antisense knockdown of c-iap2 abolished CD40-induced enhancement of
eosinophil survival. Sputum cells from asthmatic...

...through induction of c-IAP2 expression and suggest a role for this
mechanism in allergic **inflammation** .

27/K/8   (Item 1 from file: 155)

11994848   PMID: 12209092
**CD40 engagement enhances eosinophil survival through induction of
cellular inhibitor of apoptosis protein 2 expression: Possible involvement
in allergic** inflammation .
Bureau Fabrice; Seumois Gregory; Jaspar Fabrice; Vanderplasschen Alain;
Detry Bruno; Pastoret Paul-Pierre; Louis Renaud; Lekeux Pierre
Department of Physiology, Faculty of Veterinary Medicine, University of
Liege, Belgium.

**...survival through induction of cellular inhibitor of apoptosis protein
2 expression: Possible involvement in allergic** inflammation .
... of the inhibitor of apoptosis protein (IAP) family, namely cellular
(c)-IAP1, c-IAP2, and **XIAP** , and 2 antiapoptotic proteins of the Bcl-2
family, namely Bcl-x(L) and Bfl...
... staining with propidium iodide and FITC-conjugated annexin-V. c-IAP2
expression was inhibited with **antisense** oligonucleotides. RESULTS:
Freshly isolated eosinophils from healthy and asthmatic patients did not
express CD40. Conversely...

... Inhibition of eosinophil apoptosis was accompanied by induction of
c-IAP2 but not c-IAP1, **XIAP** , Bcl-x(L), or Bfl-1/A1 expression. **Antisense**
knockdown of c-iap2 abolished CD40-induced enhancement of eosinophil
survival. Sputum cells from asthmatic...

... through induction of c-IAP2 expression and suggest a role for this
mechanism in allergic **inflammation** .
...; IM; Cell Survival; Cells, Cultured; Eosinophilia--immunology--IM;
Eosinophils--cytology--CY;   Hypersensitivity, Immediate--pathology--PA;
Inflammation --immunology--IM; Sputum--cytology--CY

141307497   CA: 141(19)307497m   PATENT
Use of caspase inhibitors as antiviral agents, and test system for their discovery
INVENTOR(AUTHOR): Ludwig, Stefan; Planz, Oliver; Sedlacek, Hans-Harald; Pleschka, Stephan
LOCATION: Germany,
ASSIGNEE: Medinnova Gesellschaft fur Medizinische Innovationen aus Akademischer Forschung m.b.H.
PATENT: PCT International ; WO 200485682 A2 DATE: 20041007
APPLICATION: WO 2004DE646 (20040324) *DE 10313636 (20030326)
PAGES: 40 pp. CODEN: PIXXD2 LANGUAGE: German CLASS: C12Q-001/70A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ ; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

11770551   EMBASE No: 2002339725
CD40 engagement enhances eosinophil survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation
Bureau F.; Seumois G.; Jaspar F.; Vanderplasschen A.; Detry B.; Pastoret P.-P.; Louis R.; Lekeux P.
Dr. F. Bureau, Department of Physiology, Faculty of Veterinary Medicine, University of Liege, Sart Tilman, B-4000 Liege Belgium
Journal of Allergy and Clinical Immunology (J. ALLERGY CLIN. IMMUNOL.) (United States) 2002, 110/3 (443-449)
CODEN: JACIB   ISSN: 0091-6749
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH   SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 31

   ...survival through induction of cellular inhibitor of apoptosis protein 2 expression: Possible involvement in allergic inflammation

   ...of the inhibitor of apoptosis protein (IAP) family, namely cellular (c)-IAP1, c-IAP2, and XIAP , and 2 antiapoptotic proteins of the Bcl-2 family, namely Bcl-xSUBL and Bfl-1...
...staining with propidium iodide and FITC-conjugated annexin-V, c-IAP2 expression was inhibited with antisense oligonucleotides. Results: Freshly isolated eosinophils from healthy and asthmatic patients did not express CD40. Conversely...

...Inhibition of eosinophil apoptosis was accompanied by induction of
c-IAP2 but not c-IAP1, **XIAP** , Bcl-xSUBL, or Bfl-1/A1 expression.
Antisense knockdown of c-iap2 abolished CD40-induced enhancement of
eosinophil survival. Sputum cells from asthmatic...

...through induction of c-IAP2 expression and suggest a role for this
mechanism in allergic **inflammation** .
DRUG DESCRIPTORS:
propidium iodide; fluorescein isothiocyanate; lipocortin 5; **antisense**
oligonucleotide; RNA--endogenous compound--ec; unclassified drug
MEDICAL DESCRIPTORS:
*allergic asthma--etiology--et; * **inflammation** --etiology--et; *eosinophil

 27/K/11   **(Item 1 from file: 71)**
DIALOG(R)File 71:ELSEVIER BIOBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

02138183   2002219133
**CD40 engagement enhances eosinophil survival through induction of cellular
  inhibitor of apoptosis protein 2 expression: Possible involvement in
  allergic** inflammation
Bureau F.; Seumois G.; Jaspar F.; Vanderplasschen A.; Detry B.; Pastoret
P.-P.; Louis R.; Lekeux P.
ADDRESS: Dr. F. Bureau, Department of Physiology, Faculty of Veterinary
       Medicine, University of Liege, Sart Tilman, B-4000 Liege, Belgium
Journal: Journal of Allergy and Clinical Immunology, 110/3 (443-449), 2002
, United States
CODEN: JACIB
ISSN: 0091-6749
DOCUMENT TYPE: Article
LANGUAGES: English   SUMMARY LANGUAGES: English
NO. OF REFERENCES: 31

DESCRIPTORS:
Allergy; Apoptosis; Asthma; Atopy; CD40; Eosinophils; Granulocytes;
Inflammation ; Neutrophils

CLASSIFICATION CODE AND DESCRIPTION:
86.3.3.9 - IMMUNOLOGY AND INFECTIOUS DISEASES / CELLS OF THE IMMUNE SYSTEM
    / T Lymphocytes / General functions and activation
86.3.9 - IMMUNOLOGY AND INFECTIOUS DISEASES / CELLS OF THE IMMUNE SYSTEM /
    Eosinophil Leucocytes
86.8.1.4 - IMMUNOLOGY AND INFECTIOUS DISEASES / IMMUNE RESPONSE DISORDERS /
    Acute **Inflammation** , Immediate Hypersensitivity, Anaphylaxis /
    Diagnosis and therapy
89.2.5.4 - CELL AND DEVELOPMENTAL BIOLOGY / CELL GROWTH AND DIVISION /
    Cellular Senescence and Death / Death (apoptosis

...**survival through induction of cellular inhibitor of apoptosis protein 2
  expression: Possible involvement in allergic** inflammation

...of the inhibitor of apoptosis protein (IAP) family, namely cellular
(c)-IAP1, c-IAP2, and **XIAP** , and 2 antiapoptotic proteins of the Bcl-2
family, namely Bcl-xSUBL and Bfl-1...

...staining with propidium iodide and FITC-conjugated annexin-V, c-IAP2
expression was inhibited with **antisense** oligonucleotides. Results:

Freshly isolated eosinophils from healthy and asthmatic patients did not
express CD40. Conversely...
...Inhibition of eosinophil apoptosis was accompanied by induction of
c-IAP2 but not c-IAP1, **XIAP** , Bcl-xSUBL, or Bfl-1/A1 expression.
Antisense knockdown of c-iap2 abolished CD40-induced enhancement of
eosinophil survival. Sputum cells from asthmatic...

...through induction of c-IAP2 expression and suggest a role for this
mechanism in allergic **inflammation** .

DESCRIPTORS:
Allergy; Apoptosis; Asthma; Atopy; CD40; Eosinophils; Granulocytes;
Inflammation ; Neutrophils

CLASSIFICATION CODE AND DESCRIPTION:
...Acute **Inflammation** , Immediate Hypersensitivity, Anaphylaxis...

27/K/12   (Item 1 from file: 144)
DIALOG(R)File 144:Pascal
(c) 2004 INIST/CNRS. All rts. reserv.

15809300   PASCAL No.: 02-0525803
**CD40 engagement enhances eosinophil survival through induction of
cellular inhibitor of apoptosis protein 2 expression: Possible involvement
in allergic** inflammation
BUREAU Fabrice; SEUMOIS Gregory; JASPAR Fabrice; VANDERPLASSCHEN Alain;
DETRY Bruno; PASTORET Paul-Pierre; LOUIS Renaud; LEKEUX Pierre
Department of Physiology, Faculty of Veterinary Medicine, Department of
Pneumology, Faculty of Medicine, University of Liege, Liege, Belgium;
Department of Immunology/Vaccinology, Faculty of Veterinary Medicine,
Department of Pneumology, Faculty of Medicine, University of Liege, Liege,
Belgium
Journal: Journal of allergy and clinical immunology, 2002, 110 (3)
443-449
Language: English

**...survival through induction of cellular inhibitor of apoptosis protein
2 expression: Possible involvement in allergic** inflammation
... of the inhibitor of apoptosis protein (IAP) family, namely cellular
(c)-IAP1, c-IAP2, and **XIAP** , and 2 antiapoptotic proteins of the Bcl-2
family, namely Bcl-x SUB L and...

... staining with propidium iodide and FITC-conjugated annexin-V. c-IAP2
expression was inhibited with **antisense** oligonucleotides. Results:
Freshly isolated eosinophils from healthy and asthmatic patients did not
express CD40. Conversely...

... Inhibition of eosinophil apoptosis was accompanied by induction of
c-IAP2 but not c-IAP1, **XIAP** , Bcl-x SUB L , or Bfl-1/A1 expression.
Antisense   knockdown of c-iap2 abolished CD40-induced enhancement of
eosinophil survival. Sputum cells from asthmatic...

... through induction of c-IAP2 expression and suggest a role for this
mechanism in allergic **inflammation** .

English Descriptors: Asthma; Allergy; Atopy; Human; Pathogenesis;
   Eosinophil; **Inflammation** ; Granulocyte; Apoptosis; Blood; Sputum; Flow
   cytometry; Immunoblotting assay

French Descriptors: Asthme; Allergie; Atopie; Homme; Pathogenie;
   Eosinophile; **Inflammation** ; Granulocyte; Apoptose; Sang; Expectoration;
   Cytometrie flux; Methode immunoblotting; Antigene CD40; Proteine IAP

 27/K/13   (Item 2 from file: 144)
DIALOG(R)File 144:Pascal
(c) 2004 INIST/CNRS. All rts. reserv.

   14624714   PASCAL No.: 00-0295143
   **Gene therapy that inhibits nuclear translocation of nuclear factor KB
results in tumor necrosis factor alpha -induced apoptosis of human
synovial fibroblasts**
   ZHANG H G; NING HUANG; DI LIU; BILBAO L; XIAOWU ZHANG; YANG P; TONG ZHOU;
CURIEL D T; MOUNTZ J D
   University of Alabama at Birmingham, United States; Gene Therapy Program,
Birmingham, Alabama, United States; University of Alabama at Birmingham,
Birmingham, Alabama, United States; Veterans Administration Medical Center,
Birmingham, Alabama, United States
   Journal: Arthritis and rheumatism, 2000, 43 (5) 1094-1105
   Language: English

   ... factor KB (IKB) dominant-negative adenovirus (AdCMVIKB-DN) and an
X-linked   inhibitor   of   apoptosis   (**XIAP**)   **antisense**   adenovirus
(AdCMVXIAP-AS). Primary RA synovial fibroblast (RASF) cell lines were
transfected in vitro, and...

... was no apoptosis after treatment with AdCMVI kappa B-DN in the absence
of TNFa. **XIAP**   is   an   inhibitor of apoptosis which was up-regulated by
TNFa, and this up-regulation...

... greatly enhances apoptosis due to inhibition of an NF-KB-mediated
antiapoptosis signaling pathway, and **XIAP** is a TNFa-inducible specific
inhibitor of apoptosis in RA synovial cell lines. This and...
Broad Descriptors: Diseases of the osteoarticular system; **Inflammatory**
   joint disease; Immunopathology; Autoimmune disease; Cytokine; Systeme
   osteoarticulaire pathologie; Rhumatisme inflammatoire; Immunopathologie;
   Maladie autoimmune; Cytokine...

 27/K/14   (Item 1 from file: 991)
DIALOG(R)File 991:NewsRoom 2004 Jan 1-2004/Jul 31
(c) 2004 The Dialog Corporation. All rts. reserv.

0836083099 16L82K4U
POSTERS: SIGNAL TRANSDUCTION (NOT INSULIN ACTION)-CYTOKINES AND APOPTOSIS
Cao, Wen M
   Murao, Koji
   Imachi, Hitomi
   Yu, Xiao
   Et al
Diabetes, pA442

...protein bound the PRCE by EMSA and was identified by super shift assay.
Finally, PREB- **siRNA** , that inhibited the PREB expression, significantly
decreased the effect of glucose on MCP-1 promoter...

...FN mRNA and protein expression in a dose-dependent manner. HUVECs were
then transfected with **SiRNA** targeted to oncofetal FN. The transfected
endothelial cells were cultured in low (5 mmol/L...
...glucose caused upregulation of VEGF mRNA levels in the negative control
transfected cells. Transfection with **SiRNA** targeted to oncofetal FN
completely abolished glucose-induced VEGF mRNA expression. Endothelial
cells were then...

...K. KIM. New Haven, CT

We have previously shown that acute pre-treatment of anti- **inflammatory**
cytokine, interleukin (IL)-10, prevented insulin resistance associated with
5-hour lipid infusion, and the...

...Research

1859-P

Cytoprotection of Pancreatic [beta] Cells by Co-Overexpression of Bcl-2 and
 XIAP Genes Blocking TRAIL-Mediated Death-Signal Transduction Pathways

DAWEI OU, XIAJIE WANG, DANIEL L. METZGER...

...investigated the inhibitory effects of Bcl-2 and the X-linked inhibitor
of apoptosis protein (**XIAP**) on TNF-related apoptosis-inducing ligand
(TRAIL)-induced human [beta]-cell destruction. A panel of...

...type NES2Y and CM cells and the vector transfectants (P<0.0002 to 0.01).
 XIAP -overexpressed NES2Y and CM cells were developed by exposing the
cells to an infectious **XIAP** recombinant adenovirus (AdXIAP) at MOI 10.
[beta] cells infected with AdLacz were used as controls...

...AdXIAP were much less than that observed in cells transfected with
either Bcl-2 or **XIAP** alone (P<0.0004 to 0.04). Overexpression of Bcl-2
and/or **XIAP** by gene transfection inhibited TRAIL-induced activation of
caspases and TRAIL-mediated damage of mitochondrial...

...these cells suggesting the major mechanisms of regulation. These results
indicated that Bcl-2 and **XIAP** are important components of the signal
transduction pathways that regulate TRAIL-induced human [beta]-cell death
and that there may be novel therapeutic potential of Bcl-2 and **XIAP**
co-overexpression [beta] cells in type 1 diabetes.

1860-P

Protein Kinase C alpha Activation...

27/K/15   (Item 2 from file: 991)

DIALOG(R)File 991:NewsRoom 2004 Jan 1-2004/Jul 31
(c) 2004 The Dialog Corporation. All rts. reserv.

0803005993 16J605V8
OTHER NEWS TO NOTE
BioWorld Today, v15
Tuesday, March 30, 2004
JOURNAL CODE: ARME LANGUAGE: English RECORD TYPE: Fulltext
DOCUMENT TYPE: Newsletter SECTION HEADING: 60 ISSN: 1541 0595
WORD COUNT: 1,824

Aegera Therapeutics Inc., of Montreal, began Phase I trials of
AEG35156/GEM640, an **antisense** inhibitor of x-linked inhibitor of
apoptosis protein (**XIAP**), in collaboration with Cancer Research UK.
AEG35156 is a second-generation **antisense** oligonucleotide, designed to
reduce high levels of **XIAP** in cancer cells and enable cell death. The
initial trial is in patients with advanced...

...agreement with Funakoshi Ltd., of Tokyo, related to RNAx's services for
the validation of **siRNA** oligonucleotides and genetic targets based on RNA
interference technology. Funakoshi will act as exclusive agent...

...applications for endothelial differentiation gene (Edg) receptors 1
through 7 and their use in cancer, **inflammation** and other diseases.
Ceretek also transferred its cell lines incorporating chimeric Edg
receptors for screening...

 27/K/16   (Item 1 from file: 992)
DIALOG(R)File 992:NewsRoom 2003
(c) 2004 The Dialog Corporation. All rts. reserv.

0589510171 162V09XU
**Research and Markets: Targeting endogenous inhibitors of apoptosis:
Opportunities for the treatment of cancer, stroke and MS**
M2 Communications
Tuesday, February 11, 2003
JOURNAL CODE: ALPP LANGUAGE: English RECORD TYPE: Fulltext
DOCUMENT TYPE: Newswire
WORD COUNT: 1,549

...Proteins") family. This field has grown exponentially since 1995 and
continues to do so. Although **XIAP** and survivin remain the better known
members of this family, 8 human IAPs have now...

...contributed much of the data surrounding one of the most promising
targets from this family, **XIAP** .

Dr Jon Goldhill: Dr Jon Goldhill has over 10 years of academic and
industrial research...

...management at the French pharmaceutical giants, Sanofi-Synthelabo.
Focussing on a variety of indications including **inflammatory** disorders,
GI disease, Urological conditions and cancer, Dr Goldhill was responsible
for target identification and...

...apoptosis inhibitory protein; NAIP) BIRC2 (API1; HIAP2; cIAP1; MIHB)
BIRC3 (API2; HIAP1; cIAP2; MIHC) BIRC4 (**XIAP** ; API3; **MIHA** ; ILP) BIRC5

(Survivin; API4; TLAP) BIRC6 (Apollon; BRUCE) BIRC7 (MLIAP; KIAP; Livin)
BIRC8: (ILP-2...

...13-PE38 apolizumab alvocidib indisulam combretastatin A-4 Profiles of
IAP-related molecules HIAP-1 **antisense   XIAP** inhibitors AEG-161
Apoptosis inhibitors Trends in apoptosis inhibitors Apoptosis inhibitors in
development Profiles of...

 27/K/17   **(Item 1 from file: 20)**
DIALOG(R)File 20:Dialog Global Reporter
(c) 2004 The Dialog Corp. All rts. reserv.

27495364   (USE FORMAT 7 OR 9 FOR FULLTEXT)
Research   and   Markets: Targeting   endogenous   inhibitors   of   apoptosis:
   Opportunities for the treatment of cancer, stroke and MS
M2 PRESSWIRE
February 11, 2003
JOURNAL CODE: WMPR   LANGUAGE: English   RECORD TYPE: FULLTEXT
WORD COUNT: 1471

 (USE FORMAT 7 OR 9 FOR FULLTEXT)

...   Proteins") family. This field has grown exponentially since 1995
and   continues to do so. Although **XIAP** and survivin remain the better
known members of this family, 8 human IAPs have now...

... contributed much of the data surrounding one of the most promising
targets from this family, **XIAP** .
      Dr Jon Goldhill: Dr Jon Goldhill has over 10 years of academic and
industrial research...

... management at the French pharmaceutical giants, Sanofi-Synthelabo.
Focussing on a variety of indications including **inflammatory**   disorders,
GI disease, Urological conditions and cancer, Dr Goldhill was responsible
for target identification and...

... apoptosis inhibitory protein; NAIP) BIRC2 (API1; HIAP2; cIAP1; MIHB)
BIRC3 (API2; HIAP1; cIAP2; MIHC) BIRC4 (**XIAP** ; API3; **MIHA** ; ILP) BIRC5
(Survivin; API4; TLAP) BIRC6 (Apollon; BRUCE) BIRC7 (MLIAP; KIAP; Livin)
BIRC8: (ILP-2...

... 13-PE38 apolizumab alvocidib indisulam combretastatin A-4 Profiles of
IAP-related molecules HIAP-1 **antisense** . **XIAP**   inhibitors AEG-161
Apoptosis inhibitors Trends in apoptosis inhibitors Apoptosis inhibitors in
development Profiles of...

 27/K/18   **(Item 1 from file: 761)**
DIALOG(R)File 761:Datamonitor Market Res.
(c) 2004 Datamonitor. All rts. reserv.

00241838

CANCER: 1.1 THIS MONTH'S HIGHLIGHTS

Main Title: PHARMAWATCH
 Pub. Date: July 23, 2003
    Source: DATAMONITOR

...must be provided, which will be caused by a non-specific immune
activation similar to **inflammation** reactions. All three signals are

generated by dSLIM.
The study was of a five-armed...

...a tendency to interfere with similar enzymes called sheddases that play
a part in secreting **inflammatory** signals. Sheddase inhibition can cause
arthritis. BMS275291 was rationally designed using structural biology to
aim...cancer target
Scientists from AVI BioPharma have presented research data describing the
successful inhibition of **Xiap** , one of a family of genes known to inhibit
apoptosis, or programmed cell death, in cancer cells using an **antisense**
strategy.
The presentation highlighted results from a series of preclinical studies
using AVI BioPharma's Neugene **antisense** technology to block the
expression of the gene **Xiap** . In a wide variety of cancers, including
prostate cancer, the production of **Xiap** helps tumors grow by preventing
apoptosis, which would normally occur in cells damaged by chemotherapy...

...cells that have become resistant to chemotherapy typically exhibit
anti-apoptotic behavior. By using Neugene **antisense** drugs to block the
Xiap gene, the AVI scientists demonstrated that prostate cancer cells that
previously became resistant to chemotherapy can be resensitized to
chemotherapy drugs. The **Xiap** target was selected over other potential
anti-apoptotic targets, such as BCL-2, because of...

...release. "This study builds on our previous experience in several cancer
indications, using our Neugene **antisense** drugs to block select genes that
are associated with cancer progression. Target selection is a critical
component to **antisense** drug development for cancer, and with preclinical
data for **Xiap** and androgen receptor targets and clinical data for the
c-myc target, we believe we have assembled a robust **antisense** cancer
program."
GTx's Acapodene shown to reduces high-grade prostate intraepithelial
neoplasia
GTx, Inc...

...sponsored Investigational New Drug application for a clinical trial of
Lorus Therapeutics' (LORFF.OB) lead **antisense** drug, GTI-2040 in
combination with cytarabine, in patients with refractory or relapsed acute
myeloid...three cancer therapies in Biogen's product pipeline. Having
traditionally been focused on neurology and **inflammatory** diseases, Biogen
looked to find a partner more experienced in oncology. It would seem that
...

27/K/19   (Item 2 from file: 761)
DIALOG(R)File 761:Datamonitor Market Res.
(c) 2004 Datamonitor. All rts. reserv.

00240994

CANCER: 1.1 THIS MONTH'S HIGHLIGHTS

Main Title: PHARMAWATCH
 Pub. Date: July 23, 2003
    Source: DATAMONITOR
 Telephone: +44 20 7675 7000
Word Count: 3689 (2 pp.)
  Language: English

Features: TABLE
Country: WORLD
Industry: HEALTH CARE
Company Names (DIALOG Generated): Accentia Inc ; American Association for Cancer Research ; American Cancer Society ; American Gastroenterological Association ; American Society of Clinical Oncology ; American Society of Hematology ; American Urological Association ; Amgen ; AnorMed ; Ariad Pharmaceuticals ; AstraZeneca ; Aton Pharma ; ARIA ; AVI BioPharma ; Bayer ; Beatson Cancer Institute ; Beatson Oncology Centre ; Biogen Idec Inc ; Biologics License Application ; Biomira ; Biovest International ; BioTransplant ; Bone Metastases ; Breast Cancer Center of Excellence ; Bristol Myers Squibb ; British Biotech ; BMS/Celltech ; BMY ; Cancer Treatment ; Case Western Reserve University School of Medicine ; Catholic University ; Cell Therapeutics ; Celltech ; Chugai ; Committee for Proprietary Medicinal ; Corixa Corporation ; Department of Defense ; Drug Safety Monitoring Committee ; DNA ; Eli Lilly and Company ; Equal ; European Agency for the Evaluation of Medicinal Products ; European Commission ; European Committee on Proprietary Medicinal ; European Neurological Society ; Genentech ; Genta ; Georgetown University Medical Center ; German Federal Institute for Drugs ; GlaxoSmithKline ; GASTRO ; GTx Inc ; GTAC ; GTI ; Idec Biogen ; Idec Pharmaceuticals ; Immunex ; Immunology ; ImClone Systems ; Indre et Loire ; Investigational New Drug ; Ireland Cancer Center ; Ivax Corporation ; IVX ; Journal ; Leicester Royal Infirmary ; Leukemia & Lymphoma Society ; Lombardi Cancer Center ; Marketing Authorisation Application ; Medical Devices ; Medicinal Products ; MedImmune ; Memorial Sloan Kettering Cancer Center ; Merck & Co ; Merck KgaA ; Merger & Acquisition Update ; Millennium Pharmaceutical ; MAA ; MD Anderson Cancer Center ; ML ; National Cancer Institute ; Nemod Immuntherapie AG ; Netherlands Cancer Institute ; New Drug Application ; New England Journal ; Novuspharma SpA ; Nurses 's Health ; Ohio State University Medical Center ; Orphan Drug ; Other Cancers News ; Oxford BioMedica ; Pfizer ; PharmaMar ; Point ; Praecis Pharmaceuticals ; Progen Industries ; PGLAF ; PSA ; Regulatory News ; Reuters ; Roche ; Royal Liverpool University Hospital ; Royal Marsden Hospital ; Sanofi Synthelabo Research ; Southern Research Institute ; Stanford Research Institute International ; Stanford University ; State University of New York at Buffalo ; Sundsvall Hospital ; SuperGen ; Sustained Without M & A ; SRI International ; Teva Pharmaceutical ; Texas Health Sciences Center ; Texas MD Anderson Cancer Center ; University of Texas MD Anderson Cancer Center ; Titan Pharmaceuticals ; TransMolecular ; TAP ; University of Chicago ; University of Cologne Aventis Pharma and Mologen ; University of Texas Health Sciences Center ; University of Texas MD Anderson Cancer Center ; University of Wisconsin Medical School ; UK Gene Therapy Advisory Committee ; Washington Hospital Center ; Wisconsin Medical School ; Women 's Health Initiative

...must be provided, which will be caused by a non-specific immune activation similar to **inflammation** reactions. All three signals are generated by dSLIM.
The study was of a five-armed...

...a tendency to interfere with similar enzymes called sheddases that play a part in secreting **inflammatory** signals. Sheddase inhibition can cause arthritis. BMS275291 was rationally designed using structural biology to aim...cancer target

Scientists from AVI BioPharma have presented research data describing the successful inhibition of **Xiap** , one of a family of genes known to inhibit apoptosis, or programmed cell death, in cancer cells using an **antisense** strategy.

The presentation highlighted results from a series of preclinical studies using AVI BioPharma's Neugene **antisense** technology to block the expression of the gene **Xiap** . In a wide variety of cancers, including prostate cancer, the production of **Xiap** helps tumors grow by preventing apoptosis, which would normally occur in cells damaged by chemotherapy...

...cells that have become resistant to chemotherapy typically exhibit anti-apoptotic behavior. By using Neugene **antisense** drugs to block the **Xiap** gene, the AVI scientists demonstrated that prostate cancer cells that previously became resistant to chemotherapy can be resensitized to chemotherapy drugs. The **Xiap** target was selected over other potential anti-apoptotic targets, such as BCL-2, because of...

...release. "This study builds on our previous experience in several cancer indications, using our Neugene **antisense** drugs to block select genes that are associated with cancer progression. Target selection is a critical component to **antisense** drug development for cancer, and with preclinical data for **Xiap** and androgen receptor targets and clinical data for the c-myc target, we believe we have assembled a robust **antisense** cancer program."

GTx's Acapodene shown to reduces high-grade prostate intraepithelial neoplasia

GTx, Inc...

...sponsored Investigational New Drug application for a clinical trial of Lorus Therapeutics' (LORFF.OB) lead **antisense** drug, GTI-2040 in combination with cytarabine, in patients with refractory or relapsed acute myeloid...three cancer therapies in Biogen's product pipeline. Having traditionally been focused on neurology and **inflammatory** diseases, Biogen looked to find a partner more experienced in oncology. It would seem that ...

27/K/20   (Item 3 from file: 761)
DIALOG(R)File 761:Datamonitor Market Res.
(c) 2004 Datamonitor. All rts. reserv.

00203248

BIOTECH: 5.0 NEWS HEADLINES: GENOMICS

Main Title: HEALTHCARE REVIEW
 Pub. Date: November 01, 2002
    Source: DATAMONITOR
 Telephone: +44 20 7675 7000
Word Count: 2223 (2 pp.)
  Language: English

   Country: WORLD
  Industry: HEALTH CARE

Company Names (DIALOG Generated): Applera Corporation ; Applied Biosystems Group ; Asterand ; Biologics License Application ; BioMarin Pharmaceutical ; Bristol Myers Squibb ; Celera Diagnostics ; Celera Genomics Group ; Chapel Hill School ; Charles River Laboratories ; Clinical Cancer Research ; Comprehensive Cancer Center ; Genzyme Biosurgery ; Genzyme Corp ; Hybridon ; Isis Pharmaceuticals ; Jackson Laboratory ; Jefferson Medical College ; Leukaemia Research Fund ; Massachusetts General Hospital ; Merck & Co ; National Institute of Allergy and Infectious Diseases ; National Institute of Diabetes Digestive and Kidney Diseases of the National Institutes of Health; Onyvax ; Pennsylvania School ; Perlegen Sciences ; Pittsburgh Cancer Institute ; Pittsburgh School ; Proteome Systems ; Rockefeller University ; Southern Methodist University ; Stanford University Medical Center ; Target Discovery Program ; Targeted Genetics ; Texas M D Anderson Cancer Center ; Trademark Office ; University of Michigan ; University of North Carolina at Chapel Hill School ; University of Pennsylvania School of Medicine ; University of Pittsburgh Cancer Institute ; University of Pittsburgh School of Medicine ; University of Texas M D Anderson Cancer Center ; UNC ; Wake Forest University School of Medicine ; Wistar Institute

...separate lawsuits, for alleged infringement of its functional genomics US patents.
Hybridon and Aegera form **antisense** drug development collaboration
Hybridon and Aegera Therapeutics have entered into a collaboration and license agreement to research and develop an **antisense** drug targeted to the **XIAP** gene.
Sangamo granted US zinc finger DNA-binding proteins patent
Sangamo BioSciences has been granted...

...in Neuron, could help scientists devise new strategies to block the pain hypersensitivity associated with **inflammation** .
Wake Forest receives $20 million NIH grant to oversee diabetes genetics study
Wake Forest University...

...illnesses such as cancer and Alzheimer's disease.
Interim results of AVI's phase II **antisense** trial for cardiovascular restenosis confirm safety and efficacy
AVI BioPharma has released positive interim results of a phase II clinical trial measuring the safety and efficacy of its **antisense** compound, Resten-NG, when delivered via catheter during balloon angioplasty procedures.
Xenon Genetics adds two...anorexia nervosa.
Lexicon Genetics discovers new role for protein to develop antibody for treatment of **inflammation**
Lexicon Genetics has discovered a new role in the immune system for a secreted protein that may serve as a target for the development of drugs to treat **inflammation** associated with arthritis and autoimmune disease.
Targeted Genetics cystic fibrosis gene therapy meets primary endpoint...
...key problems in the disease.
Deltagen identifies a novel antibody target for potential treatment of **inflammatory** disorders
Deltagen has discovered a novel drug target, designated DT044I, for the potential treatment of **inflammatory** disorders, including rheumatoid arthritis. This target flows from the company's high-throughput identification screens...

27/K/21   (Item 4 from file: 761)

00203191

CANCER: 7.0 NEWS HEADLINES: COLORECTAL

Main Title: HEALTHCARE REVIEW
 Pub. Date: November 01, 2002
    Source: DATAMONITOR
 Telephone: +44 20 7675 7000
Word Count: 3846 (3 pp.)
  Language: English

   Country: WORLD
  Industry: HEALTH CARE
Company Names (DIALOG Generated): Access Pharmaceuticals ; Actinium
         Pharmaceuticals ; Adherex Technologies ; Advanced Viral
         Research ; Advectus Life Sciences ; American Association for
         the Advancement of Science ; Arius Research ; AxCell
         Biosciences ; AEterna Laboratories ; Biomira ; Bioniche Life
         Sciences ; BioCryst Pharmaceuticals ; Cancer Research ; Cell
         Therapeutics ; Chugai Pharmaceutical ; Clinical Cancer Research
         ; Comprehensive Cancer Center ; Cytogen ; CIMYM ; Dana
         Farber/Partners ; FDA 's Office of Orphan Products Development
         ; Genentech ; Genta ; GenVec ; Guilford Pharmaceuticals ; GPC
         Biotech ; Holden Comprehensive Cancer Center ; Hybridon ; HL ;
         Idec Pharmaceuticals ; IntraBiotics Pharmaceuticals ; Isis
         Pharmaceuticals ; Jackson Laboratory ; King Pharmaceuticals ;
         Leland Stanford Junior University ; Leukaemia Research Fund ; M
         D Anderson Cancer Center ; Maxim Pharmaceuticals ; Maxygen ;
         Mayne Group ; Mayo Clinic Cancer Center ; Medical Devices ;
         Memorial Sloan Kettering Cancer Center ; Merck ; Montefiore
         Medical Center ; MGI Pharma ; National Cancer Institute ;
         NeoTherapeutics ; New Drug Application ; Nippon Shinyaku ;
         North Carolina Brain Tumor Center ; Novartis Ophthalmics ;
         Orphan Products Development ; Ortho Biotech ; Oxford
         GlycoSciences ; OSI Pharmaceuticals ; Peregrine Pharmaceuticals
         ; Pharmaceutical Research and Manufacturers ; Pittsburgh Cancer
         Institute ; Protein Design Labs ; Rockefeller University ;
         Royal North Shore Hospital ; Southern Methodist University ;
         Stanford University ; SLIL Biomedical ; Texas M D Anderson
         Cancer Center ; National Cancer Institute ; Ohio State
         University ; University of Iowa ; University of North Carolina
         Brain Tumor Center ; University of Texas MD Anderson Cancer
         Center ; Trademark Office ; University of California at San
         Francisco ; University of North Carolina at Chapel Hill ;
         University of Pittsburgh Cancer Institute ; University of Texas
         M D Anderson Cancer Center ; University of Wisconsin ;
         University of Zurich ; UNC ; Vical ; Vion Pharmaceuticals ;
         Viventia Biotech ; Washington University School of Medicine

...a terminal brain cancer for which there is no known cure.
Hybridon and Aegera form **antisense** drug development collaboration
Hybridon and Aegera Therapeutics have entered into a collaboration and
license agreement to research and develop an **antisense** drug targeted to

the **XIAP** gene.
National Institutes of Health funds Seattle Genetics prodrug study
Seattle Genetics has won a...

...and neck radiation therapy used in the treatment of various cancers.

Isis awarded patent for **antisense** compounds
Isis Pharmaceuticals has been issued a US patent covering **antisense**
compounds targeted to genes encoding p38 mitogen activated protein kinases
or p38 MAP kinases. p38 MAP kinases regulate many biological processes
related to **inflammatory** diseases and cancer.
Vical stops Allovectin-7 melanoma program
Vical Incorporated has discontinued its low...

27/K/22   (Item 5 from file: 761)
DIALOG(R)File 761:Datamonitor Market Res.
(c) 2004 Datamonitor. All rts. reserv.

00203178

REVIEW: 36.0 NEWS HEADLINES: ALLIANCES AND JOINT VENTURES

Main Title: GLOBAL HEALTHCARE
 Pub. Date: November 01, 2002
    Source: DATAMONITOR
 Telephone: +44 20 7675 7000
Word Count: 1481 (1 pp.)
  Language: English

   Country: WORLD
  Industry: HEALTH CARE
Company Names (DIALOG Generated): Alza Corporation ; American Heart
          Association ; Aventis Pasteur ; AAI International ; AM Pharma
          Holding ; Bayer ; Blue Cross & Blue Shield ; Cambridge Antibody
          Technology ; Cancer Treatment ; Cel Sci ; Center for Drug
          Evaluation and Research of the FDA ; Chugai ; Epicyte
          Pharmaceutical ; Genentech ; Genta ; Hybridon ; Institute 's
          Molecular Radiation ; Ista Pharmaceuticals ; Kos
          Pharmaceuticals ; Merck & Co ; National Cancer Institute ;
          National Institute of Diabetes Digestive and Kidney Diseases of
          the National Institutes of Health; Nautilus Biotech ; Naval
          Medical Research Center of the US Navy ; New Drug Application ;
          Organogenesis ; Perlegen Sciences ; Pharma ; ProMetic Life
          Sciences ; Radiation Oncology Sciences Program ; Raptiva ;
          Senju Pharmaceutical Co ; Speedel Group ; Tanabe Holding
          America ; Tanabe Seiyaku ; University of North Carolina ; US
          National Cancer Institute ; Wake Forest University School of
          Medicine ; Xoma

...treatment of HIV-1 infection in combination with other antiretroviral
agents.
Hybridon and Aegera form **antisense** drug development collaboration
Hybridon and Aegera Therapeutics have entered into a collaboration and
license agreement to research and develop an **antisense** drug targeted to
the **XIAP** gene.
Raptiva achieves primary efficacy endpoint in phase III psoriasis study
Results of a randomized...certain other COX-inhibiting nitric
oxide-donators in Japan in the treatment of pain and **inflammation** .

Cambridge Antibody Technology and Chugai enter novel human monoclonal
antibodies development partnership
Cambridge Antibody Technology...

27/K/23   (Item 6 from file: 761)
DIALOG(R)File 761:Datamonitor Market Res.
(c) 2004 Datamonitor. All rts. reserv.

00203164

REVIEW: 25.0 NEWS HEADLINES: COLORECTAL

Main Title: GLOBAL HEALTHCARE
 Pub. Date: November 01, 2002
    Source: DATAMONITOR
 Telephone: +44 20 7675 7000
Word Count: 1274 (1 pp.)
  Language: English

   Country: WORLD
  Industry: HEALTH CARE
Company Names (DIALOG Generated): Access Pharmaceuticals ; American
         Association for the Advancement of Science ; AxCell Biosciences
         ; Biomira ; Clinical Cancer Research ; Cytogen ; Genta ; GenVec
         ; Guilford Pharmaceuticals ; Hybridon ; Isis Pharmaceuticals ;
         Maxim Pharmaceuticals ; Maxygen ; Merck ; National Cancer
         Institute ; New Drug Application ; Ortho Biotech ; Peregrine
         Pharmaceuticals ; Pharmaceutical Research and Manufacturers ;
         Pittsburgh Cancer Institute ; Royal North Shore Hospital ;
         National Cancer Institute ; University of Pittsburgh Cancer
         Institute ; Vical ; Vion Pharmaceuticals

...a terminal brain cancer for which there is no known cure.
Hybridon and Aegera form **antisense** drug development collaboration
Hybridon and Aegera Therapeutics have entered into a collaboration and
license agreement to research and develop an **antisense** drug targeted to
the **XIAP** gene.
National Institutes of Health funds Seattle Genetics prodrug study
Seattle Genetics has won a...

...and neck radiation therapy used in the treatment of various cancers.

Isis awarded patent for **antisense** compounds
Isis Pharmaceuticals has been issued a US patent covering **antisense**
compounds targeted to genes encoding p38 mitogen activated protein kinases
or p38 MAP kinases. p38 MAP kinases regulate many biological processes
related to **inflammatory** diseases and cancer.
Vical stops Allovectin-7 melanoma program
Vical Incorporated has discontinued its low...

27/K/24   (Item 7 from file: 761)
DIALOG(R)File 761:Datamonitor Market Res.
(c) 2004 Datamonitor. All rts. reserv.

00203161

REVIEW: 23.0 NEWS HEADLINES: GENOMICS

Main Title: GLOBAL HEALTHCARE
  Pub. Date: November 01, 2002
      Source: DATAMONITOR
  Telephone: +44 20 7675 7000
Word Count: 1079 (1 pp.)
  Language: English

  Country: WORLD
  Industry: HEALTH CARE
Company Names (DIALOG Generated): Biologics License Application ; BioMarin
          Pharmaceutical ; Genzyme Biosurgery ; Genzyme Corp ; Hybridon ;
          Isis Pharmaceuticals ; Jackson Laboratory ; Leukaemia Research
          Fund ; Massachusetts General Hospital ; Merck & Co ; National
          Institute of Allergy and Infectious Diseases ; National
          Institute of Diabetes Digestive and Kidney Diseases of the
          National Institutes of Health; Pennsylvania School ; Perlegen
          Sciences ; Southern Methodist University ; Stanford University
          Medical Center ; University of North Carolina ; University of
          Pennsylvania School of Medicine ; UNC ; Wake Forest University
          School of Medicine ; Wistar Institute

...separate lawsuits, for alleged infringement of its functional genomics
US patents.
Hybridon and Aegera form **antisense** drug development collaboration
Hybridon and Aegera Therapeutics have entered into a collaboration and
license agreement to research and develop an **antisense** drug targeted to
the **XIAP** gene.
Sangamo granted US zinc finger DNA-binding proteins patent
Sangamo BioSciences has been granted...

...in Neuron, could help scientists devise new strategies to block the pain
hypersensitivity associated with **inflammation** .
Wake Forest receives $20 million NIH grant to oversee diabetes genetics
study
Wake Forest University...

...illnesses such as cancer and Alzheimer's disease.
Interim results of AVI's phase II **antisense** trial for cardiovascular
restenosis confirm safety and efficacy
AVI BioPharma has released positive interim results of a phase II clinical
trial measuring the safety and efficacy of its **antisense** compound,
Resten-NG, when delivered via catheter during balloon angioplasty
procedures.
Xenon Genetics adds two...

 27/K/25   (Item 1 from file: 993)
DIALOG(R)File 993:NewsRoom 2002
(c) 2004 The Dialog Corporation. All rts. reserv.

0513541041 15Y3182J
OTHER NEWS TO NOTE.
BioWorld Today, v13, n179, pNA
Wednesday, September 18, 2002
JOURNAL CODE: AAFH LANGUAGE: English RECORD TYPE: Fulltext
DOCUMENT TYPE: Newsletter
WORD COUNT: 2,759

...validate a number of drug targets associated with cancer. Atugen will develop GeneBlocs, specially designed **antisense** oligonucleotides, which inhibit expression of specific drug target candidates selected by Schering. Though specific financial...

...of Montreal, formed an agreement in which Hybridon will collaborate with Aegera to develop an **antisense** drug candidate targeted to down-regulate Aegera's target, **XIAP** , which has been implicated in the resistance of cancer cells to chemotherapy. The drug candidate...

...Hybridon licensed to Aegera, on a nonexclusive basis, rights to a portfolio of second-generation **antisense** chemistries and oral **antisense** delivery intellectual property owned or licensed by Hybridon. Aegera will pay Hybridon certain collaboration, up...

...a license to certain Isis patents for target validation and functional genomics using first-generation **antisense** oligonucleotides in exchange for undisclosed payments from Sequitur. Subject to a limited right to conclude existing contracts, Sequitur agreed to not practice in the field of second- or next- generation **antisense** oligonucleotides, also known as chimeric **antisense** oligonucleotides.

Keryx Biopharmaceuticals Inc., of Cambridge, Mass., following successful pre-Phase III meetings with the...

...an orally active small- molecule agent that targets a cell-surface protein involved in the **inflammatory** response. The dose-escalation trial will be conducted in up to 30 healthy adult volunteers...

...that Vasogen's immune modulation therapy can significantly reduce cell death induced by lipopolysaccharide, an **inflammatory** stimulus. The attenuation of the **inflammatory** response was associated with an increase in the anti- **inflammatory** cytokine interleukin-10 and a concomitant decrease in the pro- **inflammatory** cytokine interleukin- 1B. The therapy also led to a reduction in the expression of certain enzymes involved in the intracellular response to **inflammation** , including the stress-activated protein kinase c-Jun NH(2)-terminal kinase.

COPYRIGHT 2002 A...

27/K/26   (Item 2 from file: 993)
DIALOG(R)File 993:NewsRoom 2002
(c) 2004 The Dialog Corporation. All rts. reserv.

0505054968   15XL1PPR
Death receptor-mediated apoptosis and the liver
Yoon, Jung-Hwan
Journal of Herpetology, v37, n3, p400
Sunday, September 1, 2002
JOURNAL CODE: AMRR LANGUAGE: English RECORD TYPE: Fulltext
DOCUMENT TYPE: Scholarly Journal ISSN: 0022-1511
WORD COUNT: 7,958

...produced by macrophages including Kupffer cells, monocytes, and T cells in response to infection and **inflammatory** conditions, but also by other cell types, such as B cells, fibroblasts, and hepatocytes. Unlike...

...proteins that regulate the cytochrome c/Apaf- 1 caspase activating pathway [23]. Three human IAPs, **XIAP** , c-IAP-1 and c-IAP-2, have been shown to bind procaspase 9 and...

...hepatitis [57]. Fas expression can be induced either by virus-- specific protein expression or by **inflammatory** cytokines such as interleukin-1. Activated CTLs express Fast and induce hepatocyte apoptosis via Fas...
...to eliminate hepatocytes bearing CCC DNA. Since limited apoptosis can delete cells without inducing untoward **inflammatory** reactions, the differential sensitivity of HBV-infected hepatocytes to TRAIL-induced apoptosis could potentially be...

...DRs use caspase 8/10 and Bid to induce apoptosis, targeted caspase inhibition and Bid **antisense** oligonucleotides could be therapeutically useful in cholestatic liver diseases. For example, Bid **antisense** oligonucleotides have already been shown to be therapeutically useful in a rodent model of extrahepatic...strategy to inhibit liver fibrogenesis. Alternatively, apoptosis in the liver by DRs may be pro- **inflammatory** . For example, administration of Fas agonists in the rodent results in liver chemokine expression, which...

...Lugering N, Held J, Domschke W, et al. Caspase activation correlates with the degree of **inflammatory** liver injury in chronic hepatitis C virus infection. Hepatology 2001;34:758-767.

[57] Mochizuki...

...677.
[71] Higuchi H, Miyoshi H, Bronk SF, Zhang H, Dean N, Gores GJ. Bid **antisense** attenuates bile acid-induced apoptosis and cholestatic liver injury. I Pharmacol Exp Ther 2001;299...

...J, Xing Z. Macrophage engulfment of apoptotic neutrophils contributes to the resolution of acute pulmonary **inflammation** in vivo. Am J Respir Cell Mol Biol 1995;12:232-237.

[77] Fadok VA...

...Campe CB, Schrum LW, Rippe RA, et al. Anti-Fas induces hepatic chemokines and promotes **inflammation** by an NF-kappa B-independent, caspase-3-dependent pathway. J Biol Chem 2001;276...
? T S28/MEDIUM,K/ALL
>>>KWIC option is not available in file(s): 398, 399

 28/K/1   (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

11277558   PMID: 11356694
  X-linked   inhibitor   of   apoptosis   protein   activates   the phosphatidylinositol 3-kinase/Akt pathway in rat granulosa cells during follicular development.
  Asselin E; Wang Y; Tsang B K
  Reproductive   Biology   Unit   and   Division   of   Reproductive   Medicine, Department   of   Obstetrics   and   Gynecology   and   Cellular   and   Molecular Medicine, University of Ottawa, Canada.

Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

X-linked inhibitor of apoptosis protein (**XIAP**) in granulosa cells is regulated by gonadotropins during follicular development, although the current understanding of the mechanisms by which **XIAP** suppressed granulosa cell apoptosis is incomplete. In the present study, we investigated the possible involvement...
... development and atresia in immature rats, we have demonstrated that gonadotropin treatment increased granulosa cell **XIAP** and phospho-Akt protein contents and suppressed apoptosis. In addition, gonadotropin withdrawal [equine CG (eCG...

... apoptosis and significantly decreased ovarian weight. The increased apoptosis was accompanied by marked decreases in **XIAP** expression and phosphorylation of Akt protein. Infection of granulosa cells from eCG-primed rats with adenoviral sense **XIAP** [lacZ as a control; multiplicity of infection, 1-5] resulted in **XIAP** overexpression and increased phospho-Akt content, whereas **XIAP** **antisense** expression (multiplicity of infection, 10-40) decreased granulosa cell phospho-Akt level and induced apoptosis...

... the first time the importance and regulation of the PI 3-K survival pathway by **XIAP** in the control granulosa cell apoptosis.
...; Cultured; Chorionic Gonadotropin--administration and dosage--AD; Chorionic Gonadotropin--immunology--IM; Chorionic Gonadotropin --pharmacology--PD; **Follicular Atresia** ; In Situ Nick-End Labeling; Oligodeoxyribonucleotides, **Antisense** --genetics--GE; Ovarian Follicle --metabolism--ME; Phosphorylation; Proteins--genetics--GE; Rats; Rats, Sprague-Dawley; Transfection
Chemical Name: Antibodies; Chorionic Gonadotropin; IAP-like protein, vertebrate; Oligodeoxyribonucleotides, **Antisense** ; Proteins; Proto-Oncogene Proteins; proto-oncogene protein akt; 1-Phosphatidylinositol 3-Kinase

28/K/2 **(Item 1 from file: 159)**
DIALOG(R)File 159:Cancerlit

02728648 21255627 PMID: 11356694
X-linked inhibitor of apoptosis protein activates the phosphatidylinositol 3-kinase/Akt pathway in rat granulosa cells during follicular development.
Asselin E; Wang Y; Tsang B K
Reproductive Biology Unit and Division of Reproductive Medicine, Department of Obstetrics and Gynecology and Cellular and Molecular Medicine, University of Ottawa, Canada.
Document Type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

X-linked inhibitor of apoptosis protein (**XIAP**) in granulosa cells is

regulated by gonadotropins during follicular development, although the current understanding of the mechanisms by which **XIAP** suppressed granulosa cell apoptosis is incomplete. In the present study, we investigated the possible involvement...
... development and atresia in immature rats, we have demonstrated that gonadotropin treatment increased granulosa cell **XIAP** and phospho-Akt protein contents and suppressed apoptosis. In addition, gonadotropin withdrawal [equine CG (eCG...

... apoptosis and significantly decreased ovarian weight. The increased apoptosis was accompanied by marked decreases in **XIAP** expression and phosphorylation of Akt protein. Infection of granulosa cells from eCG-primed rats with adenoviral sense **XIAP** [lacZ as a control; multiplicity of infection, 1-5] resulted in **XIAP** overexpression and increased phospho-Akt content, whereas **XIAP** antisense expression (multiplicity of infection, 10-40) decreased granulosa cell phospho-Akt level and induced apoptosis...

... the first time the importance and regulation of the PI 3-K survival pathway by **XIAP** in the control granulosa cell apoptosis.
   Minor Descriptors: Antibodies--pharmacology--PD; Apoptosis; Cells, Cultured; **Follicular Atresia** ; Gonadotropins, Chorionic--administration and dosage--AD; Gonadotropins, Chorionic--immunology--IM; Gonadotropins, Chorionic--pharmacology--PD; In Situ Nick-End Labeling; Oligodeoxyribonucle otides, **Antisense** --genetics--GE; Ovarian Follicle--metabolism--ME; Phosphorylation; Proteins--genetics--GE; Rats; Rats, Sprague-Dawley; Transfection
   Chemical Name: Antibodies; Gonadotropins, Chorionic; IAP-like protein, vertebrate; Oligodeoxyribonucleotides, **Antisense** ; Proteins; Proto-Oncogene Proteins; proto-oncogene protein akt; 1-Phosphatidylinositol 3-Kinase